Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Education and Training in Anesthesia and Intensive Care Medicine: Current Challenges and Future Directions" in Advances in Medical Education and Practice.

Anesthesia and intensive care medicine are rapidly evolving disciplines in which patient safety, technological advancement, and increasing clinical complexity place high demands on clinicians. High-quality education and training are therefore essential to ensure not only technical proficiency, but also strong decision-making, communication, and teamwork skills. In recent years, training frameworks have increasingly moved toward competency-based approaches that emphasize clearly defined outcomes and demonstrated clinical competence rather than time-based progression. This shift aims to improve transparency, consistency, and quality of training across diverse healthcare systems. However, it also requires adaptation of curricula, teaching strategies, and assessment methods, as well as an expanded role for educators as facilitators, assessors, and role models. Exploring effective approaches to education and professional development is thus central to sustaining excellence in anesthesia and intensive care medicine.

This is important because anesthesia and intensive care medicine have a direct impact on patient safety and perioperative outcomes in high-risk clinical settings. As patients become older and more complex and technologies more advanced, clinicians must be equipped to deliver safe, effective care under pressure. Modern, competency-based training supports the acquisition of both technical expertise and essential non-technical skills such as decision-making, communication, and teamwork. Clear and standardized training frameworks promote consistency, quality, and equity across institutions and healthcare systems, while also reducing errors and improving outcomes. Investing in education and professional development in anesthesia and intensive care is therefore a core patient safety and healthcare quality priority.

The general theme of this Article Collection is the contemporary approach to medical education in anesthesia and intensive care. Topics of interest include curriculum development, innovative and interactive teaching strategies, modern assessment methods, integration of non-technical skills, simulation-based education, and the development of new standards that promote fair, equitable, and patient-centred care. All article types are welcome, including viewpoints, narrative or systematic reviews, original research, surveys, and observational studies.
Keywords

• Anesthesiology education
• Intensive care training
• Competency-based medical education
• Curriculum development
• Professional development

Please review the journal’s aims and scope and author instructions prior to submission. Please submit your manuscript through the Dovepress website. During submission, enter the promo code 3B60D to indicate that your article should be considered for this Collection. The manuscript submission deadline is 31 March 2027.

Please contact Francis Straw at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisor

Professor Vojislava Neskovic is a staff anesthetist and Associate Professor of Anesthesia and Intensive Care at the Military Medical Academy in Belgrade, Serbia. Since 2012, she has also contributed to the ESAIC Teach the Teachers (TTT) Masterclass, where she is a member of the TTT Masterclass Committee. Professor Neskovic is one of the authors of the UEMS European Training Requirements for the specialty of anesthesiology, pain, and intensive care medicine. She serves as an examiner for the Part Two EDAIC (European Diploma in Anaesthesiology and Intensive Care) and hosts the Part One (written) EDAIC examination in Belgrade. Currently, she is a member of the EACTA Thoracic Subcommittee, represents Serbia as a Council Member of the ESAIC, and is a member of the WFSA Diversity, Equity and Inclusion (DEI) Committee.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Transformative Learning: The Next Step in Medical Education" in Advances in Medical Education and Practice.

Medical education finds itself at a crossroads. As healthcare systems grow increasingly complex, facing pressures from demographic shifts, rising costs, and enduring and increasing health disparities, educators are called to prepare future professionals not only to function within these systems, but to transform them. Traditional pedagogical models often fall short in equipping learners with the mindset, competencies, adaptability, and critical consciousness needed for a role as change agent. Transformative learning theory offers a compelling response. Rooted in fostering deep, structural shifts in perspective, this educational approach enables learners to question assumptions, engage in critical reflection, and develop the capacity to act ethically and innovatively in the face of uncertainty. As medical education seeks to remain relevant and future-oriented, the integration of transformative learning becomes increasingly vital.

Embracing transformative learning in medical education is not merely theoretical: it is a practical necessity. Healthcare professionals must be prepared to navigate moral complexity, collaborate across and beyond academic disciplines, and confront the hidden curriculum that shapes professional identity. Transformative learning encourages these capabilities by supporting learners in making meaning from experience, developing agency, and challenging existing power structures. When integrated into medical education, it fosters a culture of continuous learning, critical inquiry, and social responsibility. Such a shift can enhance professional resilience, promote equity in care, and ultimately contribute to the sustainability of healthcare systems. In doing so, transformative learning has the potential to empower healthcare workers not just to adapt to change, but to lead it.

This Article Collection invites contributions that explore the integration, theory, and practice of transformative learning in medical education. We welcome a range of article types, including empirical research (both qualitative and quantitative), conceptual papers, case studies, curriculum innovation reports, and commentaries. Submissions may address topics such as the design of transformative learning environments, critical reflection practices on transformative learning theory, inter- and trans-disciplinary education, the role of the hidden curriculum, embodied learning, and the development of change agency and change makers among learners. Contributions should align with the journal’s focus on advancing health professions education through scholarship and innovation. By gathering diverse perspectives and experiences, this collection aims to shape a new narrative in health professions education, one that places transformation at its core.

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code F1E5A to indicate that your article should be considered for this Collection. The manuscript submission deadline is 31 July 2026.

Please contact Francis Straw at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisors

Dr. Efraim Hart, OLVG / VU University, Amsterdam, Netherlands

[email protected]

Dr. Efraim Hart is a medical doctor, a PhD-candidate, and education consultant from the Netherlands. His research is focused on health activism and transformative learning.

Dr. Frederique Demeijer, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

[email protected]

Dr. Frederique Demeijer is an assistant professor at the Athena Institute of the Vrije Universiteit Amsterdam. Her research and education are centred around complex societal issues, which she aims to address by working together with diverse groups in a transdisciplinary setting. Her current research focuses on transformative learning, inter- and transdisciplinary education and research, competency development, and community engaged learning.

Prof. Dr. Fedde Scheele, University of Amsterdam & Vrije Universiteit, Amsterdam, Netherlands

[email protected]

Prof. Dr. Fedde Scheele is Dean of ACTA (Faculty of Dentistry, Amsterdam), Professor of Health Systems Innovation and Education at VU University Amsterdam, and Chair of European Foundation for Women’s Health. His research focuses on designing socially relevant, future-oriented healthcare education, and his goal is to deliver respectful healthcare in an open culture where education, research, and societal responsibility flourish.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Breast Cancer Biomarkers in Diagnostic and Translational Pathology" in Breast Cancer: Targets and Therapy.

Breast cancer diagnostics has undergone a significant transformation with the expanding integration of immunohistochemistry-based biomarker assessment into routine pathology practice. Beyond traditional morphologic classification, contemporary evaluation increasingly incorporates predictive and prognostic markers. In breast pathology, biomarkers such as hormone receptors and HER2 have long served as foundational tools; however, recent developments have broadened this landscape to include more nuanced categories of expression and emerging targets. This evolving framework reflects a shift toward more refined histopathologic evaluation. As a result, breast cancer pathology now sits at the intersection of diagnostic evaluation and translational science, with biomarker assessment forming a core component of how these tumors are classified and understood.

Breast cancer diagnostics has undergone a significant transformation with the expanding integration of immunohistochemistry-based biomarker assessment into routine pathology practice. Beyond traditional morphologic classification, contemporary evaluation increasingly incorporates predictive and prognostic markers. In breast pathology, biomarkers such as hormone receptors and HER2 have long served as foundational tools; however, recent developments have broadened this landscape to include more nuanced categories of expression and emerging targets. This evolving framework reflects a shift toward more refined histopathologic evaluation. As a result, breast cancer pathology now sits at the intersection of diagnostic evaluation and translational science, with biomarker assessment forming a core component of how these tumors are classified and understood.

This Article Collection will focus on investigating immunohistochemical and molecular biomarker testing in breast cancer, with particular emphasis on optimizing reproducibility and standardization in routine practice.

Topics of interest include (but are not limited to):

• Technical and interpretative challenges that pathologists and oncologists must consider, especially in the assessment of low and ultra-low HER2 expression and their implications for targeted therapies.
• Predictive biomarkers in breast cancer immunotherapy, as well as emerging markers that inform treatment selection and response.
• Integration of digital pathology approaches and translational surgical pathology studies.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

The deadline for submissions is 31 January 2027. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code C2928 to indicate that your submission is for consideration in this Article Collection.

Please contact Rebecca Turner at [email protected] with any questions or requests for discount codes relating to this Article Collection.

Guest Advisors

Dr. Eyas Alzayadneh is a surgical pathologist with training in gynecologic and breast pathology. His work focuses on the integration of histopathologic, immunohistochemical, and molecular features in tumor evaluation and clinical practice. He has contributed to research across multiple areas of cancer pathology, with an interest in biomarker-based diagnostics and their clinical applications.

Dr. Rofieda Radi Abdel Rahman Alwaqfi is an Assistant Professor of Pathology at the Johns Hopkins Hospital.

View all papers in this article collection

Cancer stem cells (CSCs) are a therapy-resistant subpopulation that drives tumor initiation, progression, metastasis, and recurrence. Their capacity for self-renewal, plasticity, and adaptation underpins resistance to chemotherapy, radiotherapy, and immunotherapy, making them a central obstacle to long-term therapeutic success. Eradicating CSCs is thus recognized as a critical goal in improving long-term patient survival.

However, CSC research and targeted therapy face numerous challenges. Currently, there is a lack of universally applicable CSC-specific biomarkers, making it difficult to precisely target CSCs without damaging normal stem cells. Furthermore, CSCs continuously interact with the tumor microenvironment, including hypoxic homeostasis, matrix support, and immune regulation; these external conditions further enhance CSC survival and drug resistance. Recent advances in single-cell omics, spatial omics, and artificial intelligence technologies have provided new tools for revealing the heterogeneity, metabolic characteristics, and regulatory networks of CSCs. Based on these technological innovations, new strategies such as metabolic inhibition, synthetic biology intervention, and immunotherapy are being studied to target CSCs, with the potential to overcome CSC-mediated therapeutic resistance.

This Article Collection aims to gather the latest research progress in the field of cancer stem cells and to facilitate exchange and discussion on key issues such as drug resistance mechanisms, biomarker discovery, and clinical translation. Selected high-quality contributions from the 2026 International Conference on New Models for Cancer Prevention and Treatment (NMCPT 2026, http://www.nmcpt.com/), together with externally submitted manuscripts, will be included. Both original research articles and authoritative reviews are welcome.

Topics of interest include, but are not limited to:
• Molecular Mechanisms & Biomarkers: Intrinsic and microenvironment-mediated resistance pathways; discovery and validation of CSC-associated biomarkers for diagnosis, prognosis, and treatment stratification.
• Tumor Ecosystem: The role of the tumor microenvironment (immune, stromal, metabolic) in sustaining CSCs and fostering therapeutic escape.
• Innovative Therapeutics: Novel strategies targeting CSC vulnerabilities, including small molecules, immunotherapies, epigenetic modulators, and rational combination therapies.
• Translational & Clinical Research: Preclinical validation in advanced models (e.g., patient-derived organoids, in vivo models); pilot and early-phase clinical trials of CSC-targeting agents; studies on minimal residual disease and recurrence.

Submitting authors are eligible for a 10% discount on the Article Publishing Charge. To apply this discount, enter the code B4C3A when prompted during submission.

Manuscript deadline:
31 October 2026

Guest Advisor:
Dr. Peixin Dong, Hokkaido University, Japan, [email protected]

View all papers in this article collection

Taylor & Francis’s Gastroenterology and Hepatology journals, together with Guest Advisors Professor Henning Grønbæk, Professor Knut Lundin, and Associate Professor Purnima Bhat, are pleased to invite you to submit your research to the Article Collection “Innovations in Gastroenterology & Hepatology.”
The Collection aims to discuss clinically focused papers highlighting novel successes in precision medicine, from innovations at a molecular level all the way through to diagnostics and treatments in a variety of settings (including low resource).

Possible subtopics include:

• Novel multi-omic molecular / biomarker technologies for diagnosis, treatment response and prognosis in hepatology and gastroenterology
• Repurposing and recycling in low-resource settings 
• Novel imaging technologies 
• Novel diagnostic and therapeutic endoscopic tools 
• Wearable technologies 
• Robotics 
• Point-of-care diagnostics
• Novel therapeutics 
• Precision medicine 
• Digital health and artificial Intelligence in hepatology and gastroenterology
• Remote patient care and telehealth / telemedicine 
• Novel endoscopy techniques. 
• Psychosocial treatment innovations 
• New strategies and improvements in healthcare system approaches 

The collection spans both Open Access and hybrid journals including: Clinical and Experimental Gastroenterology, Hepatic Medicine: Evidence and Research, Colorectal Cancer, Expert Review of Gastroenterology & Hepatology, Gastrointestinal Oncology: Management and Care, Hepatic Oncology and Scandinavian Journal of Gastroenterology. See here for more information on the journals included and our Guest Advisors.

All Manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript. 

The deadline for submissions is 15 January 2027.

Please submit your manuscript on our website, quoting the promo code 0D8F7 to indicate that your submission is for consideration in this Article Collection.

For any questions or discount queries regarding the Collection, please email Rebecca Kearns at [email protected].

Guest advisors

Professor Purnima Bhat, Canberra Hospital and Australian National University

Professor Knut E A Lundin, University of Oslo

Professor Henning Grønbæk

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Aging in Otolaryngology – Head and Neck Surgery" in Clinical Interventions in Aging.

Demographic shifts toward an increasingly aged global population demand heightened attention to age-related pathophysiology within otorhinolaryngology–head and neck surgery. This Article Collection explores the multifaceted impact of senescence on audiovestibular, sinonasal, laryngopharyngeal, and head and neck surgical disciplines. Conditions such as presbycusis, presbystasis, presbylarynx, presbyphagia, and age-related immunosenescence present distinctive diagnostic and therapeutic challenges. Molecular mechanisms underlying age-related deterioration - including oxidative stress pathways, mitochondrial dysfunction, and altered inflammatory cascades - warrant particular consideration.

Moreover, geriatric frailty and polypharmacy significantly influence perioperative risk stratification and postoperative rehabilitation. The intersection of gerontology and otolaryngology–head and neck surgery requires innovation in clinical approaches, including targeted interventions that address the unique physiological, cognitive, and functional considerations of the older patient population within this surgical domain.

The significance of age-focused otolaryngology is multidimensional. Demographically, individuals over 65 years will constitute an increasing proportion of the global population in the coming decades, accompanied by a growing incidence of age-related otolaryngologic conditions. Clinically, senescent changes in head and neck structures directly affect speech, voice, swallowing, breathing, hearing, and balance - fundamental aspects of human function. Economically, appropriately tailored interventions can reduce healthcare expenditures through fewer complications and hospitalizations. Scientifically, advancing our understanding of the molecular basis of otolaryngologic aging contributes to broader gerontological paradigms. Ethically, addressing these age-related conditions supports dignity, autonomy, and quality of life, representing both a clinical priority and a moral imperative.

We invite systematic reviews, state-of-the-art reviews, and original research articles that examine the impact of aging across the full spectrum of otolaryngology–head and neck surgery. Submissions may address clinical, translational, or basic science aspects in the following areas, including but not limited to:

• Laryngology: age-related voice disorders (presbylarynx), dysphagia (presbyphagia), laryngeal neuromuscular degeneration, and innovations in diagnosis and voice therapy or surgical interventions for older adults
• Head and Neck Surgery: surgical outcomes, risk stratification, reconstructive techniques, and perioperative management in geriatric patients undergoing procedures for benign or malignant conditions
• Oncology: epidemiology, tumor biology, and treatment responses of head and neck cancers in older adults
• Otology and Neuro-otology: presbycusis, balance disorders (presbystasis), cochlear implantation in the elderly, age-related central auditory processing, and vestibular rehabilitation strategies
• Rhinology: chronic rhinosinusitis, olfactory dysfunction, age-associated mucosal changes, and surgical or medical management tailored to geriatric physiology

A focus will be done for innovation in medical and surgical fields of otolaryngology in older adults.

Please submit your manuscript on our website, quoting the promo code A944F to indicate that your submission is for consideration in this Article Collection.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 July 2026.

Guest Advisors:

Jerome R. Lechien, University of Mons, Belgium

[email protected]

Jerome R. Lechien is professor and chair of surgery in University of Mons, Belgium. He is consultant in robotic and laryngeal surgery in Foch Hospital, Paris, France and member of several scientific societies, including American College of Surgery (ACS), ABEA, CEORL, UEP, and ELS.

Lise Sogalow, University of Mons, Belgium

[email protected]

Dr. Sogalow is medical doctor and PhD candidate in Artificial Intelligence in University of Mons, Belgium.

Antonino Maniaci, University of Enna

[email protected]

Prof. Dr. Antonino Maniaci, born in Messina in 1989, is an Associate Professor of Otolaryngology at the University of Enna Kore, Italy, specializing in rhinology, head and neck oncology, and sleep apnea disorders. He holds a Ph.D. in Biomedical Sciences and has completed advanced training and fellowships in prestigious institutions across Europe, including Marseille and Forlì. With over 287 scientific publications and an H-index of 27, his research focuses on inflammatory and oncological diseases, genetic alterations, and innovative treatments in otolaryngology. He serves as European Secretary of YoIFOS and is actively involved in coordinating international research projects, conferences, and fellowships. Prof. Maniaci has received numerous awards, is a member of editorial boards of high-impact journals, and frequently speaks at international conferences.

View all papers in this article collection

We are pleased to announce a new Article Collection in Clinical Interventions in Aging, titled: Biomarker-Guided Clinical Interventions in Geriatric Heart Failure: From Phenotyping to Practice.

Heart failure (HF) affects over 64 million people worldwide and disproportionately burdens adults aged 65 and above, in whom clinical presentation, comorbidity burden, and physiological reserve differ markedly from younger patients. In this population, guideline-directed medical therapies — including renin-angiotensin-aldosterone system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — produce variable effects on biomarkers of inflammation, neurohormonal activation, and cardiorenal stress, with evidence specific to older adults remaining limited. Understanding how clinical interventions modify these biological signals, whether changes in these biomarkers predict downstream outcomes such as mortality and HF hospitalization, and how biomarker-informed phenotyping can personalize therapeutic decision-making, represents one of the most pressing challenges in current geriatric cardiology.

The aging HF population is not homogeneous. Older adults with HF span a spectrum from the relatively fit patient with isolated left ventricular dysfunction to the frail, multimorbid individual with cardiorenal-hepatic syndrome and limited tolerance for aggressive pharmacotherapy. Emerging evidence indicates that circulating inflammatory markers (interleukin-6, CRP, GDF-15), cardiorenal biomarkers (cystatin C, NGAL), and neurohormonal indicators respond differentially to pharmacological, device-based, and rehabilitative interventions depending on the patient’s phenotypic subtype. Identifying which interventions most effectively normalize these biomarkers — and which patient subgroups benefit most — has direct implications for risk stratification and treatment personalization in older adults.

This Article Collection invites original research, systematic reviews, and narrative reviews examining how clinical interventions in older adults with HF influence biomarker profiles, phenotypic trajectories, and patient outcomes. Relevant subtopics include: the effects of pharmacological therapies (SGLT2 inhibitors, ARNIs, mineralocorticoid receptor antagonists) on inflammatory, neurohormonal, and cardiorenal biomarkers in patients aged 65 and above; the impact of device-based therapies (ICD, CRT, LVAD) and structured cardiac rehabilitation on biomarker levels and phenotypic classification in geriatric HF cohorts; biomarker-guided treatment titration and serial monitoring strategies in older adults with acute or chronic HF; machine learning and phenotyping approaches that identify which patient subgroups derive the greatest benefit from specific interventions; sex-, ethnicity-, and geography-specific variation in biomarker responses to clinical interventions; and real-world multicentred data on intervention outcomes in older adults with HF, including frail and multimorbid subgroups. Studies from diverse geographic regions, including Asia, Europe, and the Americas, are particularly encouraged.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer review if they can pass the desk assessments as part of our standard editorial process; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please submit your manuscript on our website. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 January 2027.

Please contact Catherine Teng at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisors

Dr Thien Tan Tri Tai Truyen, Cedars Sinai Medical Center

[email protected]

Dr. Truyen is a cardiovascular researcher at the Smidt Heart Institute, Cedars-Sinai Medical Center, working within the Center for Cardiac Arrest Prevention. His research focus sudden cardiac death, geriatric heart failure phenotyping, and machine learning-based risk stratification, with publications in Circulation: Arrhythmia and Electrophysiology, JACC: Advances, and JAHA. He serves as an Academic Editor for Frontiers in Medicine and PLOS ONE, and completed advanced training through Harvard Medical School's Global Clinical Scholars Research Training Program. He is also a current fellow of American College of Cardiology.

Dr Loc Vu, School of Medicine, Tan Tao University

[email protected]

Physician-scientist specializing in cardiovascular research and coronary hemodynamics. I am actively engaged in clinical training and research, with work recognized internationally, including multiple American Heart Association – Paul Dudley White International Scholar Awards (2021–2024), the top abstracts score at AHA 2022, and awards from the European Society of Cardiology. I also serve as a Social Media Ambassador for the Cardiovascular Research Foundation (CVRF, Korea) and as the Founder and Managing Director of the Doctor Plus platform, a physician-led initiative with over 130,000 followers.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Comprehensive Management of Complex Cataracts: Surgical Innovations and Postoperative Strategies" in Clinical Ophthalmology.

Complex cataracts represent a diverse group of challenging cases that require advanced surgical skills, tailored techniques, and meticulous perioperative care. These cases may involve coexisting ocular comorbidities, traumatic cataracts, zonular instability, small pupils, corneal opacities, pseudoexfoliation, uveitis-related lens changes, or high myopia. The variability in presentation demands that surgeons not only master technical adaptations but also integrate multidisciplinary management approaches to optimize patient outcomes. 

As global cataract surgery volumes rise, the proportion of cases with added complexity is increasing. Inadequate planning or inappropriate intraoperative decision-making in such cases can lead to sight-threatening complications and poor visual rehabilitation. At the same time, recent innovations - from femtosecond laser-assisted cataract surgery and capsular tension devices to advanced intraocular lens (IOL) technologies and enhanced imaging - offer unprecedented opportunities to improve safety and outcomes. By systematically addressing complex cataracts through both surgical and post-surgical lenses, clinicians can reduce complication rates, enhance visual quality, and improve patients’ quality of life. 

This Article Collection seeks to explore all aspects of complex cataract management, including preoperative evaluation, surgical decision-making, intraoperative innovations, complication prevention, and comprehensive postoperative care. 

Subtopics may include: 

• Surgical approaches for eyes with weak zonules, coexisting corneal pathology, or previous ocular surgeries
• Management of cataracts in uveitis, glaucoma, or high myopia
• IOL selection and fixation techniques
• Perioperative medical management
• Rehabilitation strategies

We welcome original research articles (including surgical technique papers), review articles, perspectives, and commentaries.

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 9B736 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.

The manuscript submission deadline is 31 August 2026. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest advisers

Dr. Bharat Gurnani, Gomabai Netralaya and Research Centre, Neemuch, Madhya Pradesh, India

Dr. Kirandeep Kaur, Gomabai Netralaya and Research Centre, Neemuch, Madhya Pradesh, India

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "The Choroid in Health and Disease" in Clinical Ophthalmology.

The investigation of choroidal dynamics has been gaining increasing and critical interest in the recent years due to its pervasive involvement in the pathogenesis and progression of numerous sight-threatening chorioretinal disorders. Choroidal structural, circulatory, or inflammatory perturbations are now recognized as a core etiology in multiple conditions including age-related macular degeneration, pathological myopia, central serous chorioretinopathy and related pachychoroid disorders, hypertensive and diabetic eye disease, and diverse posterior uveitides.

Crucially, the recent advancements of non-invasive imaging modalities, notably swept-source optical coherence tomography (OCT) and widefield OCT, has propelled in vivo assessment of the choroid, facilitating quantitative analysis of its thickness, vasculature, and underlying morphological changes. This technological leap now facilitates essential quantitative analysis of its thickness, vasculature, and underlying morphological changes. These tools are the foundation for the next generation of diagnostics and treatment monitoring.

This Article Collection, "The Choroid in Health and Disease", aims to gather cutting-edge research illuminating the complex physiological and pathological states of this essential tissue. We solicit contributions covering the latest advancements in:

• Quantitative choroidal imaging and biometrics
• The choroid's role in the refractive error pathway and myopia control
• Choroidal vascular alterations in systemic conditions
• The mechanistic contribution of choroidal changes to macular pathologies
• Novel insights into choroidal inflammation, immunology, and targeted therapeutics

We welcome the submission of original research articles, rigorous systematic reviews, and technically-focused brief reports that contribute significantly to the molecular, structural, and clinical understanding of choroidal biology.

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 14701 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.

The manuscript submission deadline is 1 August 2026. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest advisors

Dr. Yousef Fouad, Ain Shams University, Egypt

Dr. Sumit Randhir Singh, Akhand Jyoti Eye Hospital Center of Excellence, India

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Clinical Pharmacology and Pharmacotherapeutics of Anti-Infective Agents" in Clinical Pharmacology: Advances and Applications.

This Article Collection focuses on the clinical pharmacology and therapeutic applications of anti-infective agents, including antibiotics, antivirals, antifungals, and antiparasitic drugs. It aims to explore pharmacokinetic/pharmacodynamic (PK/PD) relationships, drug interactions, resistance mechanisms, and individualized dosing strategies in diverse patient populations. The Collection also welcomes research on novel therapeutic approaches, therapeutic drug monitoring (TDM), and the optimization of anti-infective regimens in clinical practice.

The global rise in antimicrobial resistance and the challenges in treating complex infections underscore the urgent need for advanced pharmacological insights. Understanding the clinical pharmacology of anti-infectives is critical for maximizing efficacy, minimizing toxicity, and curbing resistance. This Collection seeks to bridge the gap between pharmacological science and clinical practice, supporting evidence-based therapeutic decisions and contributing to global antimicrobial stewardship efforts.

We invite submissions of Original Research, Reviews, Case Reports, and Perspectives that align with the scope of the journal. Topics of interest include but are not limited to: PK/PD modeling of anti-infectives, TDM in special populations, drug–drug interactions, pharmacogenomics, resistance mechanisms, and clinical outcomes related to anti-infective therapy. All submissions should adhere to the journal’s guidelines and will undergo full peer review.

Keywords

• Anti-infective agents
• Clinical pharmacology
• Pharmacotherapeutics
• PK/PD modeling
• Antimicrobial stewardship

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 30 September 2026.

Please submit your manuscript on our website, quoting the promo code 7189C to indicate that your submission is for consideration in this Article Collection.

Please contact Catherine Teng at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr Bin Lin, Changxing People’s Hospital

[email protected]

Dr Jiao Xie, The Second Affiliated Hospital of Xi'an Jiaotong University

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection on “Phototherapy in Dermatology and Cosmetology: Current Advances, Clinical Applications, and Future Directions” in Clinical, Cosmetic and Investigational Dermatology.

Phototherapy has become an essential and rapidly evolving modality in dermatology and cosmetology, offering effective, non-invasive treatment options for a wide range of skin conditions. The use of ultraviolet (UV), visible light, and laser-based technologies has significantly improved therapeutic outcomes in inflammatory, autoimmune, pigmentary, and neoplastic skin disorders, as well as in aesthetic and anti-aging procedures.

This Article Collection aims to highlight recent advances in phototherapeutic techniques, including narrowband UVB, PUVA, excimer light, photodynamic therapy (PDT), low-level light therapy (LLLT), and emerging laser and LED-based systems. Emphasis is placed on clinical applications, treatment protocols, mechanisms of action, safety considerations, and patient-specific approaches in both medical and cosmetic dermatology.

In addition, this Collection seeks to explore translational research and technological innovations shaping the future of phototherapy, such as personalized light-based treatments, combination therapies, artificial intelligence–assisted treatment planning, and novel photosensitizers. By integrating basic science, clinical evidence, and forward-looking perspectives, this Collection aims to provide clinicians, researchers, and industry professionals with a comprehensive overview of the current state and future potential of phototherapy in dermatology and cosmetology.

Phototherapy plays a crucial role in patient care because it offers effective, evidence-based treatment options that are both non-invasive and well tolerated. For many dermatological and cosmetological conditions, phototherapy provides significant clinical improvement while minimizing the need for systemic medications, which may be associated with serious side effects or long-term risks.

Key subtopics include, but are not limited to: Mechanisms of action of phototherapy and light–skin interactions; Clinical applications in dermatology (e.g., psoriasis, atopic dermatitis, vitiligo, acne, cutaneous lymphoma); Photodynamic therapy and novel photosensitizers; Laser and light-based technologies in cosmetology and aesthetic medicine; Treatment safety, adverse effects, and long-term outcomes; Personalized and combination phototherapy approaches; Technological innovations, including LED systems, targeted phototherapy, and AI-assisted treatment planning.

Keywords

1. Phototherapy
2. Skin diseases
3. Light-based therapies
4. Dermatology
5. Cosmetology

Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 10 November 2026.

Please submit your manuscript on our website, quoting the promo code 914F0 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.

Guest editors

Dr Karolina Chilicka-Hebel, Department of Health Sciences, Institute of Health Sciences, University of Opole, Opole, Poland

[email protected]

Professionally, a research and teaching staff member, professor at the Institute of Health Sciences, University of Opole. Coordinator of the scientific group “Modern Cosmetology”. As a lecturer, specializes in cosmetic devices, while as a researcher focuses on studies on the effects of modern devices on the skin condition of people suffering from common acne.

Dr Danuta Nowicka, Division of Aesthetic Dermatology and Regenerative Medicine of the Skin, Wroclaw Medical University, 50-368 Wroclaw, Poland

[email protected]

A Polish physician and scientist, specializing in dermatology and venereology. She is a university professor and lecturer, affiliated among others with the Medical University and the University of Physical Education in Wrocław. She conducts scientific, teaching, and clinical work and is also the author of publications in the field of dermatology.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection on “Wound healing: future prospects” in Clinical, Cosmetic and Investigational Dermatology.

In the United States, where millions of people suffer from chronic wounds (CWs), wound healing (WH) is a significant public health problem. Over 1.5 million individuals in Europe have CWs, a problem made worse by an aging population and growing diabetes rates. The basic principles of wound healing are still not fully understood, despite the need for innovation in healing technology to enhance patient outcomes. Progress in this difficult subject that requires the integration of several medical disciplines is hampered by the existing concentration on specialized themes without sufficient interdisciplinary cooperation. To overcome these issues, recent initiatives have focused on genetic diversity, regeneration vs scarring, and neuro-immune integration.

Progress in this difficult subject that requires the integration of several medical disciplines is hampered by the existing concentration on specialized themes without sufficient interdisciplinary cooperation. To overcome these issues, numerous cellular components, including mast cells, T regulatory cells, and dendritic stem cells, as well as molecular elements like genetics, have been highlighted in recent studies on wound healing. Important neural mediators for healing have been identified by neuro-immunomodulation, and comprehension of the process depends on the activation of microbiota. Future studies should incorporate genetics, neuro-immune signaling, and microbiome interactions.

Wound healing (WH) is a major public health concern, particularly in the U.S. where millions are affected by chronic wounds (CWs). This issue is exacerbated by an aging population and rising diabetes rates. Despite the need for innovation in healing technologies to improve patient outcomes, there remains a lack of comprehensive understanding of wound healing's biological principles.

We therefore welcome submissions regarding articles on the cellular constituents of the healing process, as well as molecular aspects. Given the growing interest in neuroimmunomodulation, proposals on this topic are welcome. Finally, articles on the activity of the microbiota are undoubtedly useful for a deeper understanding of the mechanisms underlying wound healing. All of this is useful in clinical practice.

Article types for the Collection: Research Articles, Review, Commentary, Opinion, short communication

Keywords

1. Wound healing
2. Acute wounds
3. Chronic wounds
4. Mast cells
5. cellular infiltrate

Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 8 March 2027.

Please submit your manuscript on our website. Please note that normal Article Processing Charges will apply.

Guest editor

Prof. Dr. Stefano Bacci, University of Florence

[email protected]

Prof. Dr. Stefano Bacci is a Professor of Cytology and Histology and Developmental Biology at the University of Florence, with a training at the Schepens Eye Research Institute, Harvard Medical School. His primary research focuses on cellular mechanisms in wound healing and he has authored over 100 significant articles in this field.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Behavioral and Psychosocial Aspects in the Management and Treatment of Diabetes and Obesity" in Diabetes, Metabolic Syndrome and Obesity.

Diabetes and obesity remain major challenges for modern societies, not only because of their rising prevalence but also due to the substantial burden they place on people living with these conditions and their families. Although medical care has advanced significantly—with new medications, improved insulin formulations, and modern technologies—clinical outcomes often remain suboptimal. Increasing evidence highlights that behavioral and psychosocial factors play a crucial role in the effectiveness of treatment and long-term outcomes. Psychological functioning, self-management behaviors, emotional distress, and social context interact with biological and medical factors in shaping the course of diabetes and obesity.

It seems unlikely that progress in managing diabetes and obesity will result from identifying a single crucial factor. Rather, improvement is expected to come from recognizing and addressing a range of contributing factors.

Despite remarkable progress in pharmacotherapy and technological innovations, many individuals still experience challenges achieving optimal disease management. Behavioral barriers, psychosocial burden, and difficulties in sustaining effective self-management remain major contributors to unmet needs in diabetes and obesity care. Improving behavioral and psychosocial support may therefore represent one of the most transformative avenues for enhancing treatment outcomes. This Article Collection aims to gather studies that deepen understanding of behavioral and psychosocial mechanisms and translate this knowledge into practical strategies that can improve management, adherence, and quality of life.

This Collection focuses exclusively on behavioral and psychosocial aspects relevant to the management and treatment of diabetes and obesity. We particularly welcome submissions addressing:

• Behavioral determinants of diabetes and obesity management: self-care behaviors, adherence, lifestyle patterns, motivation, decision-making, and behavioral interventions.
• Psychosocial mechanisms influencing the course and treatment of diabetes and obesity: emotional distress, coping styles, well-being, social support, stigma, self-efficacy, illness perceptions.
• Behavioral and psychosocial aspects of technology use: psychological adaptation to diabetes technologies, human-technology interaction, digital burden, digital literacy, and the impact of technology on self-management behaviors.
• Interventions integrating behavioral and psychosocial components: structured education, psychotherapy, digital behavioral programs, and multidisciplinary approaches.
• Psychosocial and behavioral dimensions of obesity as a risk factor for diabetes: lifestyle behaviors, weight-related distress, family and social influences.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, entering the promo code 503C6 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 30 September 2026.

Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Kokoszka Andrzej, The Medical University of Warsaw, Poland

[email protected]

Tomasz Klupa, Department of Metabolic Diseases Jagiellonian University Medical College, Poland

[email protected]

Katarzyna Cyranka, Unit of Psychodiabetology, Department of Metabolic Diseases Jagiellonian University Medical College

Department of Psychiatry Jagiellonian University Medical College, Poland

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Environmental Determinants of Obesity and Diabetes: Endocrine Disruptors, Pollutants, and Metabolic Risk" in Diabetes, Metabolic Syndrome and Obesity.

The global rise in obesity and diabetes has traditionally been attributed to lifestyle factors such as diet and physical inactivity; however, accumulating evidence highlights the critical contribution of environmental determinants to metabolic disease. Among these, endocrine-disrupting chemicals (EDCs) and environmental pollutants have emerged as key drivers of metabolic dysregulation. Widely present in air, water, soil, and consumer products, these agents interfere with hormonal signaling pathways that regulate energy balance, adipogenesis, glucose homeostasis, and appetite. Early-life and chronic exposures—often occurring as complex chemical mixtures—have been shown to induce persistent alterations in metabolic programming. Mechanistic insights suggest that pollutants can act as “obesogens” and “diabetogens,” promoting adipocyte differentiation, insulin resistance, and systemic inflammation through pathways involving nuclear receptors, oxidative stress, and epigenetic modifications. This growing body of research supports the concept that environmental exposures are integral components of the metabolic disease continuum, extending beyond traditional behavioral risk factors.

Understanding the environmental determinants of obesity and diabetes is essential given the scale and accelerating burden of these conditions worldwide. Non-communicable diseases account for the majority of global morbidity and mortality, and environmental factors are estimated to contribute substantially to this burden. Urbanization and industrialization have increased human exposure to pollutants, including particulate matter, persistent organic pollutants, heavy metals, and endocrine disruptors, which collectively promote systemic inflammation, oxidative stress, and metabolic dysfunction. These exposures may act across the life course, beginning in utero and extending into adulthood, thereby amplifying disease susceptibility and contributing to intergenerational transmission of risk. Importantly, environmental influences may partially explain the discordance between genetic predisposition and the rapid rise in metabolic diseases observed over recent decades. Addressing these factors has profound implications for prevention strategies, public health policies, and clinical risk stratification, emphasizing the need to integrate environmental health into metabolic disease research and management frameworks.

This Article Collection aims to provide a comprehensive platform for advancing research on the environmental drivers of metabolic disease, with a focus on endocrine disruptors and pollution-related exposures. Topics of interest include, but are not limited to, the role of specific chemical classes such as bisphenols, phthalates, PFAS, pesticides, and heavy metals; the metabolic effects of air pollution and particulate matter; mechanisms involving adipogenesis, insulin resistance, mitochondrial dysfunction, and inflammation; and the contribution of epigenetic regulation, gut microbiota alterations, and transgenerational inheritance. Studies addressing the exposome concept, mixture effects, and vulnerability during critical developmental windows are particularly encouraged. The Collection welcomes a range of article types, including original research articles, systematic reviews, narrative reviews, and translational or clinical studies that bridge experimental findings with human health outcomes. Interdisciplinary approaches integrating endocrinology, metabolism, environmental science, and public health are especially valuable to deepen understanding and inform preventive and therapeutic strategies.

Keywords

1. Endocrine disruptors
2. Environmental pollution
3. Obesity
4. Diabetes mellitus
5. Metabolic risk

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 28 February 2027.

Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr. Mustafa Cesur, Ankara Guven Hospital

[email protected]

Dr. Mustafa Cesur is a Professor of Endocrinology and Metabolic Diseases. He earned both his medical degree and his specialization in Endocrinology and Metabolic Diseases from the Ankara University Faculty of Medicine.

Currently, he serves as a Board Member of the International Society of Endocrinology (ISE) and holds various positions within the European Society of Endocrinology (ESE). He is also the national delegate for Türkiye at the Union Européenne des Médecins Spécialistes (UEMS).

Throughout his academic career, Dr. Cesur served at Ufuk University and Yüksek İhtisas University within the Department of Internal Medicine, Division of Endocrinology and Metabolic Diseases. He is currently the Head of the Department of Endocrinology and Metabolic Diseases at Ankara Güven Hospital.

His leadership in national medical societies is extensive; he served as the Secretary of the Hypertension, Obesity, and Dyslipidemia Study Group of the Society of Endocrinology and Metabolism of Türkiye (SEMT) between 2010 and 2014, and as the President of the Turkish Diabetes Society (TDS) from 2016 to 2021. Following his tenure as the Vice President of SEMT between 2021 and 2023, he led the organization as President from 2023 to 2025.

Dr. Cesur's primary clinical interests encompass diabetes, obesity, dyslipidemia, and thyroid diseases, topics on which he has published extensively and delivered numerous congress presentations. Beyond his clinical and academic work, he is deeply engaged in the history of endocrinology, both within Türkiye and on a global scale.

Dr. Arzu Or Koca, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Türkiye

[email protected]

Dr. Arzu Or Koca is an Associate Professor of Endocrinology and Metabolic Diseases. She graduated from the Faculty of Medicine at Gazi University in 2012. She completed her residency in Internal Medicine and has been practicing as an Internal Medicine Specialist since 2016. In 2020, she completed her subspecialty training in Endocrinology and Metabolic Diseases.
She is currently working as an Associate Professor at the University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Endocrinology and Metabolic Diseases.
Dr. Or Koca holds several active roles in national and international scientific organizations. She serves as the Vice Chair of the Hypertension, Obesity and Epidemiology Working Group of the Turkish Society of Endocrinology and Metabolism (SEMT). She is also the Vice Chair of the Endocrine Disruptors Commission within SEMT. In addition, she is a member of the Thyroid Study Group of the Turkish Society of Endocrinology and Metabolism. She actively contributes to the European Society of Endocrinology (ESE) State of Endocrinology Task Force – Turkiye Team.

Dr. Or Koca continues to contribute to the advancement of endocrinology through clinical research, national guideline development, and interdisciplinary collaborations, with a growing focus on real-world data and environmental determinants of endocrine diseases.

Dr. Ozge Telci Caklili, Kocaeli City Hospital

[email protected]

Dr. Ozge Telci Caklili is an Associate Professor of Endocrinology and Metabolic Diseases. She earned her Endocrinology and Metabolic Diseases degree from Istanbul University Faculty of Medicine. She also has a PhD from Istanbul Medeniyet University.
Currently, she serves as Vice President of the Early Career Working Group of the Turkish Society of Endocrinology and Metabolism. She is a member of the European Society of Endocrinology (ESE) and the State of Endocrinology Task Force of ESE. She is also a member of the European Atherosclerosis Society (EAS) and the Turkish Metabolic Syndrome Society.
She is an investigator of INTERSTROKE and PURE studies. Throughout her career she has published more than 70 publications and her current H index is 12.
She is interested in diabetes, obesity, dyslipidemia, pituitary and adrenal diseases.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Global Trends in Type 1 and Severe Insulin Sufficient Diabetes: Incidence, Diagnosis and Management" in Diabetes, Metabolic Syndrome and Obesity.

Recent years have seen a change in the diagnostic classification scheme for type 1 diabetes, such that persons with severe insulin deficiency and presentation with diabetic ketoacidosis at diagnosis, but in the absence of classic type 1 diabetes autoantibodies, are now classified as having type 2 diabetes rather than type 1 diabetes. How this may influence the treatment, or change the treatment, of persons with diabetes is of great importance in terms of the acute care of individuals with diabetes. Further, it is of great importance in terms of financial and other resources made available to both the individual and the broader regions affected by these changes, as the reclassification largely affects persons in African or South Asian countries or with predominant ancestry from those countries. Recent years have also seen an increase in the use of electronic medical record systems in the surveillance of diabetes. The incidence of Type 1 diabetes continues to rise; the new classification scheme which now places individuals who would formerly have been classified as having type 1 diabetes as type 2 diabetes may underestimate the increases in incidence rates. Conversely, the widespread trend of using EHR systems as surveillance systems for the incidence of diabetes may overestimate these rates as well as increase the misclassification of disease types.

Although acute treatment and even long-term management should be based on the clinical presentation, not diabetes type, in reality diabetes type or perceived diabetes type influences clinical decision-making. Further, while diabetes genotype or phenotype, does not discriminate based on the patient’s phenotype (for example, type 1 diabetes does not discriminate based on obesity or race/ethnicity), with widespread emphasis placed on classical phenotypes of type 1 diabetes, clinical classification decisions may eventually follow suit. While clinical treatment should be based on clinical presentation, the perceived seriousness of that presentation, and thus its treatment, including life-threatening diabetic ketoacidosis (DKA) may be influenced by the type of diabetes the individual is diagnosed with. Long-term diabetes treatment and management, financial aid from government insurance and charitable organizations and other health care services, including health care navigation services, may also be influenced by diagnosis type.

To provide a comprehensive overview, we invite submissions covering, but not limited to, the following areas:

• Trends in the incidence of Type 2 diabetes
• Trends in the Incidence of severe insulin deficient Type 2 diabetes
• Trends in the classification of diabetes types
• Antibody use in the classification of diabetes type
• Trends in the treatment of Type 1 diabetes vs. severe insulin deficient Type 2 diabetes at diagnosis and long-term management
• Advanced diabetes technology in the treatment of type 1 diabetes and severe insulin deficient Type 2 diabetes
• The cost benefit ratio of changing diabetes classification criteria

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 28 February 2027.

Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Prof. Mark deBeor, University of Virginia, Charlottesville, USA

[email protected]

Dr. Rebecca Baqiyyah Conway, University of Colorado Anschutz Medical Campus, Aurora, USA

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Real World Evidence for the Pharmacological Treatment of Diabetes: From Clinical Trials to Routine Practice" in Diabetes, Metabolic Syndrome and Obesity.

Diabetes mellitus represents one of the most pressing global health challenges of the 21st century, affecting over 500 million adults worldwide. The pharmacological landscape for diabetes has expanded rapidly, with the introduction of incretin-based therapies, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and dual-acting agents alongside established glucose-lowering drug classes. While randomized controlled trials (RCTs) remain the gold standard for evaluating therapeutic efficacy, their strict inclusion criteria, controlled settings, and limited follow-up durations often restrict the generalizability of findings to diverse, real-world patient populations. Real world evidence (RWE), derived from electronic health records, claims databases, patient registries, and post-marketing surveillance, has emerged as an essential complement to RCT data for evaluating how antidiabetic pharmacotherapies perform in routine clinical practice. This Article Collection aims to present the latest advances in RWE research specifically pertaining to the pharmacological treatment of diabetes, ultimately informing evidence-based prescribing and clinical decision-making.

The importance of RWE for antidiabetic pharmacotherapy cannot be overstated. Despite the growing number of glucose-lowering agents available, significant gaps persist between the outcomes observed in clinical trials and those achieved in everyday practice. Patient adherence to prescribed regimens, treatment persistence over time, individualized glycemic targets, and the influence of polypharmacy and comorbidities all shape therapeutic outcomes in ways that RCTs cannot fully capture. Furthermore, regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency increasingly incorporate RWE into their drug approval and post-marketing evaluation frameworks, recognizing its value in supplementing trial-based efficacy data. Understanding how specific antidiabetic drug classes and treatment sequences perform across diverse ethnicities, age groups, and comorbidity profiles is essential for optimizing individualized prescribing strategies, improving glycemic control, and reducing treatment-related adverse events in the real-world setting.

This Article Collection invites original research articles, systematic reviews, meta-analyses, and narrative reviews that utilize real world data to evaluate the pharmacological treatment of diabetes. Topics of interest include, but are not limited to: the effectiveness and safety of emerging and established glucose-lowering agents in routine clinical practice; comparative effectiveness studies of antidiabetic drug classes, including SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and insulin formulations, across diverse patient populations; real world treatment patterns, prescribing trends, and therapeutic sequencing strategies; the impact of medication adherence and persistence on glycemic control and long-term clinical outcomes; safety profiles and tolerability of antidiabetic pharmacotherapies as observed in post-marketing surveillance and pharmacovigilance databases; and health economic analyses and cost-effectiveness evaluations of glucose-lowering therapies derived from real world data sources. Contributions should align with the scope of Diabetes, Metabolic Syndrome and Obesity.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, entering the promo code E00B9 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 December 2026.

Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr. Yun Shen, Pennington Biomedical Research Center, USA

[email protected]

Prof. Gang Hu, Pennington Biomedical Research Center, USA

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Advances in p53 Drug Discovery", organized by Dr. Andreas Joerger (Goethe University, Germany), Dr. Alexander Dömling (Palacky University in Olomouc, Czech Republic) and Editor-In-Chief Dr. Frank M. Böckler (Eberhard Karls University Tübingen, Germany).

Often referred to as the "guardian of the genome", p53 plays an important role in maintaining cellular homeostasis by regulating and orchestrating cell cycle arrest, DNA repair, apoptosis, and senescence. Mutations in the TP53 gene which encodes p53, are found in a broad range of human cancers, leading to loss of its tumor-suppressive functions and contributing to cancer progression and metastasis. In addition, some gain-of-function (GOF) p53 mutants can acquire new oncogenic activities affecting genomic instability, metabolic reprogramming, and the tumor microenvironment, while promoting invasion, metastasis, and cancer cell proliferation. The complexity of p53's structure and function, particularly its role as a transcription factor and its interactions with a large number of cellular signaling pathways, has made it a challenging target for drug discovery. However, recent advances in structural biology, computational methods, and medicinal chemistry have opened new avenues for the development of drugs that can restore or enhance p53 function, offering hope for more effective cancer therapies. Furthermore, additional targets, such as MDM2/X, HAUSP, Cop-1, Pirh-2, Wip-1, PTEN, AKT, and Siah-1, could become points of therapeutic intervention, influencing p53 and its signaling and regulation network.

Playing a core role in tumor suppression, the ability to modulate p53 activity holds the potential to transform cancer treatment. The development of drugs that can restore the function of mutant p53 or enhance the activity of wild-type p53 is a critical area of research with significant implications for improving patient outcomes and survival rates in cancer.

To help raise the profile of this important area of research, Drug Design, Development and Therapy is publishing a timely Article Collection on p53 drug discovery. The Collection is led by Dr. Andreas Joerger, Prof. Dr. Alexander Dömling, and the Editor in Chief, Prof. Dr. Frank Böckler. 

Potential topics include, but are not limited to, the following:

• Structural and Molecular Biology of p53 Elucidating its Therapeutic Value
• Small Molecule Modulators of Targets Involved in p53 Signalling and Regulation
• Rescue of Loss-of-function Mutant p53 or Restraint of Gain-of-function Mutant p53
• p53-targeted Gene / Immune Therapies
• Clinical Translation of p53-based Therapies
• Challenges and Future Directions

Please submit your manuscript on our website, using the promo code XITLT for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advances in p53 Drug Discovery” Collection. We will be welcoming relevant papers up until the 30th of September 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection. 

Guest Advisors

Dr. Andreas Joerger, Goethe University

[email protected]

Andreas C. Joerger obtained his doctoral degree from the University of Freiburg, Germany in 2000. He then assumed a postdoc position in the group of Prof. Sir Alan Fersht at the Medical Research Council (MRC) Centre for Protein Engineering in Cambridge, United Kingdom, initially working on protein design. He stayed on as a senior scientist in structural biology until 2010, before moving to the MRC Laboratory of Molecular Biology in Cambridge (2010-2015). During his long spell at the MRC, he made key contributions towards unraveling the complex structural biology of the tumor suppressor p53 and related proteins. He determined the first crystal structures of p53 cancer mutants, which led to the Y220C mutant being used as a paradigm for the development of mutant p53 rescue drugs based on protein stabilization. In 2016, Dr. Joerger joined the group of Prof. Stefan Knapp at the Institute of Pharmaceutical Chemistry at Goethe University, Frankfurt am Main. Since 2018, he is Principal Investigator on p53 drug discovery and transcriptional regulation at the Structural Genomics Consortium (SGC) Frankfurt. His other research interests include the evolutionary history of the p53 pathway, protein design, epigenetic targets and E3 ubiquitin ligases. 

Dr. Alexander Dömling, Palacky University in Olomouc

[email protected]

Alex Dömling studied Chemistry & Biology at the Technische Universitat Munchen (TUM). He performed his Ph.D. with Ivar Ugi and his postdoc – funded by a Feodor Lynen stipend from the Alexander von Humboldt Foundation – with double Nobel Laureate Barry Sharpless. After his habilitation at TUM, he became a professor at the University of Pittsburgh, then chair of the Department of Drug Design at the University of Groningen, and most recently ERA Chair at Palacky University. He also started several biotech companies. He is the author of over 300 publications and over 70 patent applications. His current lab works according to the mantra ‘Automation + Miniaturization = Acceleration’ on the ERC-funded project of engineering an autonomous drug discovery platform called AMADEUS.

Alexander Dömling is a world-renowned researcher in the area of miniaturization, automation of synthetic chemistry, and multicomponent reaction chemistry. Professor Dömling applies multicomponent reaction chemistry to solve problems in drug discovery and related areas. Notably, he introduced the Acoustic Droplet Ejection technology platform to perform precise high throughput synthetic chemistry and demonstrated its applicability to multiple different chemistries and chemical biology projects.

Dr. Frank M. Böckler, Eberhard Karls University Tübingen

[email protected]

At the Institute of Pharmaceutical Sciences, Frank Böckler heads the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines Chemical Biology, Molecular and Structural Biology and Biophysics, as well as Computational Chemistry, Machine Learning and Molecular Design. In addition, he is a member of the Institute for Bioinformatics and Medical Informatics (IBMI). In 2004, he received his Ph.D. in Medicinal Chemistry with summa cum laude at Friedrich-Alexander University in Erlangen (Germany). Joining Prof. Sir Alan R. Fersht as a postdoc at the MRC Center for Protein Engineering in Cambridge/UK, he discovered p53 mutant stabilizers as potential new cancer therapeutics. In 2008, he was appointed Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich, before moving to Tübingen in 2010 as a full professor. His work is dedicated to understanding molecular interactions, such as halogen and chalcogen bonds, as the foundation for chemical biology and drug discovery and to apply theoretical, fragment-based, biophysical, and structural methods to cancer research, particularly involving the human kinome and the network of the tumor suppressor p53.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "‘Digital Drugs’ for Musculoskeletal Pain: From Evaluation Tools to Rehabilitation and Therapy Solutions", organized by Prof. Giacomo Farì (University of Salento, Italy) and Prof. Andrea Bernetti (University of Salento, Italy).

Musculoskeletal (MSK) pain represents a major global health challenge, contributing to significant disability and reduced quality of life. Conventional therapeutic approaches often fail to fully address the complex biopsychosocial dimensions of chronic pain, leading to the need for innovative, integrative strategies. In recent years, the concept of "Digital Drugs" has emerged, referring to digital health solutions that modulate pain perception through technology-driven interventions. These include virtual reality (VR), augmented reality (AR), mobile health applications, and biofeedback devices, which can reduce pain and enhance function without pharmacological side effects. By complementing classical pharmacotherapy, these digital therapeutics offer a more holistic approach to pain management, addressing both physical and psychological aspects of chronic pain. Furthermore, "Digital Drugs" provide advanced tools for evaluating pain-related behaviors and functional impairments in real-time, enabling personalized rehabilitation protocols through remote monitoring and adaptive feedback. This integrative model holds promise for optimizing musculoskeletal pain management by combining assessment, therapy, and patient engagement in a comprehensive, technology-enhanced care pathway.

Effective pain management is crucial for improving quality of life, especially in individuals suffering from chronic or complex pain conditions such as mixed pain syndromes. Traditional pharmacological treatments alone sometimes fail to fully address the multifaceted nature of chronic pain, which involves not only nociceptive and neuropathic components but also nociplastic mechanisms. Integrating multimodal approaches—such as physical therapy, psychological support, neuromodulation, and complementary therapies—provides a more comprehensive and patient-centered strategy. Notably, the combination of digital therapeutics with classical pharmacotherapy has the potential to address one of the most pressing challenges in pain management: reducing opioid reliance. By offering alternative methods to manage pain effectively, "Digital Drugs" can help mitigate the risks associated with opioid use, including dependence and adverse side effects. Addressing the biopsychosocial aspects of pain can help prevent long-term disability, reduce healthcare costs, and foster innovation in therapeutic protocols, encouraging personalized care and evidence-based clinical practice.

This Collection aims to highlight innovative approaches in the treatment, rehabilitation, and evaluation of musculoskeletal pain. Submissions of original articles and systematic reviews are encouraged on emerging strategies such as personalized pain management, integrative rehabilitation protocols, digital therapeutics, neuroplasticity-driven interventions, and advances in biomechanical and functional assessment tools. Particular interest lies in research exploring the interplay between musculoskeletal pain and psychosocial factors, as well as the implementation of remote and AI-assisted rehabilitation systems. Studies utilizing novel imaging, wearable sensors, and patient-reported outcome measures (PROMs) to enhance clinical evaluation are also welcome. Additionally, research focusing on the integration of digital therapeutics with classical pharmacotherapy to optimize treatment outcomes and improve patient care is highly encouraged. By addressing these topics, the Collection seeks to advance the understanding and application of innovative, technology-enhanced solutions for musculoskeletal pain management.

Please submit your manuscript on our website, using the promo code 8E84E to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 31st of July 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisors

Prof. Giacomo Farì, University of Salento

[email protected]

Medical Doctor, Specialized in Physical and Rehabilitation Medicine; PhD in Sport Sciences; Adjunct Professor at the University of Salento, Lecce, Italy.

Prof. Andrea Bernetti, University of Salento

[email protected]

Medical Doctor, Full Professor of Physical and Rehabilitation Medicine at the Department of Experimental Medicine – University of Salento, Lecce, Italy; General Secretary of the Italian Society of Physical and Rehabilitation Medicine.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Exploring Fragment-Based Approaches in Drug Discovery", organized by Prof. Anna K. H. Hirsch (Saarland University, Germany), Dr. Walid A. M. Elgaher (Saarland University, Germany), Prof. Oliver Koch (Universität Münster, Germany) and Editor-In-Chief, Prof. Frank M. Böckler (Eberhard Karls University Tübingen, Germany).

With the emergence of fragment-based drug discovery (FBDD), the field of drug discovery has undergone significant changes. Unlike traditional high-throughput screening techniques, FBDD is based on identifying low molecular weight compounds (fragments) with a low affinity to the biological target. These initial fragment hits are then developed into drug-like molecules through a range of techniques, including fragment merging, growing, and linking, to produce a lead with a higher affinity.

FBDD has the capacity to streamline the drug discovery process by initiating a bottom-up process of combining fragments with high ligand efficiencies. Structural insights from X-ray crystallography have fostered hopes that fragments with strong local interaction networks could be extended to target a wider binding site, often boosting the affinity substantially. The method not only increases the probability of identifying active compounds compared to random screening but also allows an in-depth exploration of the chemical and biological space surrounding these fragments. In 2024, 52 fragment-derived candidates had made it to different phases of clinical studies (phase 1–3), while seven drugs (Asciminib, Capivasertib, Erdafitinib, Pexidartinib, Sotorasib, Vemurafenib, and Venetoclax) have already been approved. This highlights the great relevance and potential of this approach for drug discovery.

To help raise the profile of this important area of research, Drug Design, Development and Therapy is publishing a timely Article Collection on fragment-based drug discovery. The Collection is led by Prof. Anna K. H. Hirsch, Dr. Walid A. M. Elgaher, Prof. Oliver Koch, and Editor in Chief, Prof. Frank M. Boeckler.

Potential topics include, but are not limited to, the following:

• Advancements in Fragment Screening Techniques
• Specialized Fragment-Libraries and Library Design
• Structural Biology and Fragment-Based Design
• Chemical Biology and Fragment Evolution
• Case Studies and Success Stories
• Challenges and Future Directions

Please submit your manuscript on our website, using the promo code SODHO for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advances in p53 Drug Discovery” Collection. We will be welcoming relevant papers up until the 31st of October 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Prof. Dr. Anna K. H. Hirsch, Saarland University, Germany

[email protected]

Anna Hirsch read Natural Sciences with a focus on Chemistry at the University of Cambridge and spent her third year at the Massachusetts Institute of Technology, doing a research project with Prof. Timothy Jamison. She carried out her Master’s research project in the group of Prof. Steven V. Ley at the University of Cambridge. She received her Ph.D. from the ETH Zurich in 2008 and worked on the de novo structure-based design and synthesis of inhibitors for an anti-infective target enzyme in the group of Prof. François Diederich. Subsequently, she joined the group of Prof. Jean-Marie Lehn at the Institut de Science et d’Ingénierie Supramoléculaires (ISIS) in Strasbourg as an HFSP postdoctoral fellow, before taking up a position as assistant professor at the Stratingh Institute for Chemistry at the University of Groningen in 2010 where she was promoted to associate professor in 2015. In 2017, she moved to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), where she heads the department for drug design and optimization. Her work focuses on anti-infective drug design by adopting rational approaches such as structure- and fragment-based drug design in combination with the target-guided strategies dynamic combinatorial chemistry and kinetic target-guided synthesis. 

Dr. Walid A. M. Elgaher, Saarland University, Germany

[email protected]

Dr. Walid A. M. Elgaher studied Pharmacy at Assiut University (Egypt). He was awarded a scholarship from the German academic exchange service (DAAD) for doctorate study in Germany. In 2016, he got his Ph.D. in Medicinal Chemistry under the supervision of Prof. Rolf W. Hartmann, Saarland University. He then returned to Egypt and was appointed as a Lecturer of Pharmaceutical Organic Chemistry at the Faculty of Pharmacy, Assiut University. In 2017, he joined the group of Prof. Anna K. H. Hirsch as a postdoctoral fellow at HIPS, and since 2024 has been a habilitand at Saarland University. His work focuses on the application of modern drug design approaches tackling un(der)exploited therapeutic targets and the use of biophysical and computational techniques for drug discovery and optimization. 

Prof. Dr. Oliver Koch, Universität Münster, Germany

[email protected]

Oliver Koch is Heisenberg-Professor of Computational Drug Discovery at the Institute of Pharmaceutical and Medicinal Chemistry, University of Münster. His interests lie in the development and application of computational methods in rational drug design with focus on ‘big data’ driven decisions and artificial intelligence combined with fragment- and structure-based design. The methods are applied to develop bioactive molecules and to understand selectivity, promiscuity and polypharmacology of protein-ligand interactions. In an interdisciplinary way, the in-silico work is combined with biochemical evaluation, x-ray crystallography and preparative organic synthesis. He received his Ph.D. in Pharmaceutical Chemistry in 2007 at Philipps-University Marburg in the group of Gerhard Klebe and also completed a postgraduate program computer science with focus on machine learning and data science. He worked as a postdoc at CCDC in Cambridge/UK and afterwards for MSD Animal Health Innovation GmbH, Schwabenheim, Germany. In 2012, he became an Independent Junior Group Leader of „In-silico Medicinal Chemistry“ at Technical University Dortmund, Germany. From 2019-22 he was Independent Group Leader for “Computational Medicinal Chemistry and Molecular Design” at University of Münster, where he became a Heisenberg-Professor for Computational Drug Discovery in 2022. 

Prof. Dr. Frank M. Böckler, Eberhard Karls University Tübingen

[email protected]

At the Institute of Pharmaceutical Sciences, Frank Böckler heads the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines Chemical Biology, Molecular and Structural Biology and Biophysics, as well as Computational Chemistry, Machine Learning and Molecular Design. In addition, he is a member of the Institute for Bioinformatics and Medical Informatics (IBMI). In 2004, he received his Ph.D. in Medicinal Chemistry with summa cum laude at Friedrich-Alexander University in Erlangen (Germany). Joining Prof. Sir Alan R. Fersht as a postdoc at the MRC Center for Protein Engineering in Cambridge/UK, he discovered p53 mutant stabilizers as potential new cancer therapeutics. In 2008, he was appointed Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich, before moving to Tübingen in 2010 as a full professor. His work is dedicated to understanding molecular interactions, such as halogen and chalcogen bonds, as the foundation for chemical biology and drug discovery and to apply theoretical, fragment-based, biophysical, and structural methods to cancer research, particularly involving the human kinome and the network of the tumor suppressor p53.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Sol Gel-Based Hybrid Materials in Drug Delivery and Biotherapeutic Stabilization", organized by Dr. Chinmay S. Potnis (Duke University, US) and Prof. Gautam Gupta (University of Louisville, US).

The development of advanced drug delivery systems is essential for improving the efficacy and shelf-life of sensitive biomolecules, including proteins, peptides, and nucleic acids. Among emerging technologies, sol gel-derived hybrid materials, particularly silica-based matrices, have gained prominence as versatile platforms for therapeutic stabilization and delivery. These materials offer mild synthesis conditions, tunable porosity, and excellent biocompatibility, allowing for the gentle encapsulation and sustained release of bioactive agents. The inorganic-organic hybrid nature imparts both structural integrity and customizable functionality, making sol gels highly adaptable for diverse pharmaceutical applications, from gene delivery to biologic preservation.

This area of research is vital, due to the inherent instability and degradation risks associated with many biologics, which can limit their therapeutic use. Sol gel materials create protective microenvironments that safeguard biomolecules while enabling site-specific and sustained delivery. Their design flexibility allows for the inclusion of targeting ligands and stimuli-responsive elements, advancing the frontiers of nanomedicine and personalized treatment. This collection highlights breakthroughs in sol gel technologies that translate to meaningful therapeutic improvements and clinical relevance.

We welcome original research articles, reviews, expert opinions, commentaries, and clinical studies aligned with the journal's scope. Topics may include sol gel synthesis and characterization, strategies for encapsulating biomolecules and small molecules, development of bioresponsive or targeted sol gels, and nanomedicine formulations. Manuscripts demonstrating translational outcomes such as in vitro and in vivo efficacy, safety profiles, and manufacturability are especially encouraged. This Collection aims to foster interdisciplinary contributions that integrate material science with drug design and therapeutic application.

Please submit your manuscript on our website, using the promo code CB47D to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 31st of October 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisor

Dr. Gautam Gupta, University of Louisville

[email protected]

Dr. Gautam Gupta is Associate Professor of Chemical Engineering. His research focuses on electrochemistry, sol gel encapsulation for biomolecules, wastewater treatment, and perovskite solar cells. Funding to support his research comes from a range of federal agencies and industrial sponsors, including NSF, NIH, DOE, EPRI and LG&E. Dr. Gupta has published extensively, has two patents, and has submitted another six research disclosures.

Dr. Chinmay S. Potnis, Duke University

[email protected]

Dr. Chinmay Potnis is a Postdoctoral Associate at Duke University with a strong background in formulation development, drug delivery, and organic synthesis. His current work focuses on designing and evaluating novel excipients to improve the stability and delivery of small-molecule drugs and nucleic acids. Through the use of silica-based sol-gels, he has developed innovative encapsulation strategies that enable controlled release and protection under stress conditions. With additional expertise in mechanistic organic synthesis, he bridges molecular design with advanced formulation approaches. He is passionate about creating scalable, real-world solutions for complex drug delivery challenges.

View all papers in this article collection

Taylor & Francis’s Gastroenterology and Hepatology journals, together with Guest Advisors Professor Henning Grønbæk, Professor Knut Lundin, and Associate Professor Purnima Bhat, are pleased to invite you to submit your research to the Article Collection “Innovations in Gastroenterology & Hepatology.”
The Collection aims to discuss clinically focused papers highlighting novel successes in precision medicine, from innovations at a molecular level all the way through to diagnostics and treatments in a variety of settings (including low resource).

Possible subtopics include:

• Novel multi-omic molecular / biomarker technologies for diagnosis, treatment response and prognosis in hepatology and gastroenterology
• Repurposing and recycling in low-resource settings 
• Novel imaging technologies 
• Novel diagnostic and therapeutic endoscopic tools 
• Wearable technologies 
• Robotics 
• Point-of-care diagnostics
• Novel therapeutics 
• Precision medicine 
• Digital health and artificial Intelligence in hepatology and gastroenterology
• Remote patient care and telehealth / telemedicine 
• Novel endoscopy techniques. 
• Psychosocial treatment innovations 
• New strategies and improvements in healthcare system approaches 

The collection spans both Open Access and hybrid journals including: Hepatic Medicine: Evidence and Research, Clinical and Experimental Gastroenterology, Colorectal Cancer, Expert Review of Gastroenterology & Hepatology, Gastrointestinal Oncology: Management and Care, Hepatic Oncology and Scandinavian Journal of Gastroenterology. See here for more information on the journals included and our Guest Advisors.

All Manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 15 January 2027.

Please submit your manuscript on our website, quoting the promo code DC842 to indicate that your submission is for consideration in this Article Collection.

For any questions or discount queries regarding the Collection, please email Rebecca Kearns at [email protected].

Guest advisors

Professor Purnima Bhat, Canberra Hospital and Australian National University

Professor Knut E A Lundin, University of Oslo

Professor Henning Grønbæk

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Future-Ready CAR-T Cells: Integrating Gene Editing, Multi-Antigen Targeting, Translational Advances and Microenvironment Reprogramming" Guest Edited by Dr. Vinay Kumar and Dr. Anuradha Tyagi in ImmunoTargets and Therapy.

Chimeric Antigen Receptor T-cell (CAR-T) therapies have transformed the landscape of cancer treatment, offering unprecedented outcomes in relapsed and refractory hematologic malignancies. Despite these breakthroughs, significant obstacles; including antigen escape, T-cell exhaustion, off-tumor toxicity, limited durability of responses, and restricted success in solid tumors still constrain their broader therapeutic potential. In parallel, rapid innovations in gene editing, synthetic biology, vector engineering, and tumor microenvironment modulation are driving the next generation of CAR-T technologies. Given the expanding field and urgent need for new solutions, this Article Collection aims to gather cutting-edge research and authoritative reviews that highlight transformative advances, emerging challenges, and forward-looking strategies in CAR-T cell–based immunotherapies.

Global research and clinical activity in CAR-T therapy is rapidly accelerating, yet critical gaps remain in mechanistic understanding, therapeutic optimization, and practical implementation. A focused collection in ImmunoTargets and Therapy will provide a comprehensive and influential resource for clinicians, immunologists, translational scientists, and biotech innovators, catalyzing advancements that can reshape patient outcomes. Hence this Article Collection, will serve as a forward-looking platform to capture breakthrough developments and foster innovation in one of the most rapidly evolving domains of modern immunotherapy.

This Collection welcomes high-impact original research, reviews, mini-reviews, perspectives/commentaries, methodology papers and graphical reviews/visual communications focusing on the diverse scientific and translational innovations reshaping CAR-T therapy. Key themes include, but are not limited to: 1. Engineering Next-Generation CAR-T Cells; 2. Addressing Antigen Escape and Heterogeneity; 3, Toxicity Mitigation and Safety Engineering; 4, Advanced Gene-Editing and Synthetic Engineering Platforms; 5, Innovations in Tumor Microenvironment (TME) Reprogramming; 6, Clinical Advances, Safety Innovations, and Combination Therapies; 7, Expanding CAR-T Horizons Beyond Cancer

Keywords

1. CAR-T cell therapy
2. Next-generation CAR-T
3. Multi-antigen targeting
4. Tumor microenvironment (TME) modulation
5. Clinical trial innovations

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code A6829 to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 15 October 2026.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Vinay Kumar, Penn State University

[email protected]

Dr. Vinay Kumar is a Researcher (junior faculty) at the Heart and Vascular Institute, Pennsylvania State University, where his work focuses on dissecting dysregulated innate and adaptive immune networks in myocardial infarction (MI) and chronic heart failure (HF). His research emphasizes understanding the roles of distinct T-cell subsets and the time-dependent phenotypic shifts these cells undergo during chronic HF. Additionally, Dr. Kumar is dedicated to developing innovative immunomodulatory strategies to reverse pathological immune alterations and facilitate their translation from bench to bedside.

Anuradha Tyagi, Department of cBRN, Institute of Nuclear Medicine & Allied Sciences

[email protected]

Dr. Anuradha Tyagi is a biomedical researcher specializing in inflammation biology, wound healing, and host–pathogen interactions. Her work demonstrates that timely modulation of the inflammatory phase is crucial for proper wound closure and tissue repair, particularly in conditions like radiation dermatitis. She has highlighted the therapeutic potential of secondary bile acids in chronic wound management, showing their ability to inhibit biofilm formation, neutralize bacterial virulence factors, modulate pro-inflammatory cytokines, and promote angiogenesis. Dr. Tyagi’s research advances our understanding of immune responses, microbial dynamics, and tissue regeneration, with important translational implications for chronic wound therapy.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Immune Targets and Novel Therapies for Systemic Lupus Erythematosus and Related Disorders" in ImmunoTargets and Therapy.

Systemic lupus erythematosus (SLE) is a prototype systemic autoimmune disease that mainly affects the younger population. Despite newer immunomodulatory therapies, the survival of the disease fails to improve since the mid-1990s. Early diagnosis and recognition of disease activity, and the use of more aggressive therapies for high-risk patients is the key to reduce disease flares, organ damage and improve quality of life. There is an unmet need to develop novel therapies with a better therapeutic index in patients suffering from SLE and related diseases such as Sjogren’s disease, undifferentiated connective tissue disease (UCTD) and systemic sclerosis. More potent B cell depletion, targeting the T cells, co-stimulatory molecules and the dendritic cells, as well as the downstream intracellular signal pathways, have been the particular spotlights of SLE therapies in recent years. Biomarker panels that help stratify patients into different subgroups enable more precise individualized therapies to improve efficacy outcomes and reduce treatment-related toxicities are being developed.

As there is an increasing number of clinical trials focusing on treating SLE/lupus nephritis (LN) published or in progress, and consensus of new assessment tools for outcome measures of clinical trials, disease activity and quality of life are being developed, it is important to start a new Collection to report/summarize the advances of the management of this class of autoimmune disorders in the areas of therapeutics, molecular mechanisms, assessment tools and biomarkers.

We welcome original works and review articles focusing on the cellular and molecular mechanisms of SLE and related disorders and their link with novel therapeutic approaches, surveillance of organ dysfunction and treatment-related toxicities, prevention of long-term organ damage and improvement of quality of life. Biomarkers that enhance the diagnostic performance of SLE/LN and related disorders, predict disease flares and prognosis of the disease, as well as response to particular therapies are also appreciated.

The focus of this Article Collection is on SLE/LN, as well as their related disorders, including systemic sclerosis, Sjogren’s disease, undifferentiated connective tissue disorder, and antiphospholipid syndrome. Areas of interest in this special Article Collection include, but are not limited to, the following:
• Genomic, transcriptomic, and metabolomic studies
• Classification criteria, disease activity indices, and organ damage
• Liquid biomarkers for the prediction of disease prognosis and flares
• Novel therapeutic, targeted agents and small molecules in disease treatment
• Cellular therapies such as CAR-T, CAR-NK, mesenchymal cells

Keywords

1. lupus
2. lupus nephritis
3. Novel therapies
4. Biomarkers
5. immunotargets
6. Systemic sclerosis
7. undifferentiated connective tissue disease
8. Sjogren’s disease

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 May 2027.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Professor Chi Chiu Mok, Tuen Mun Hospital

[email protected]

Short Biography:
Professor Mok is the Chief of Rheumatology of the Department of Medicine, Tuen Mun Hospital, Hong Kong. He is also an honorary Professor of both the University of Hong Kong University and the Chinese University of Hong Kong.
• He was the past president of the Hong Kong Society of Rheumatology and is currently the co-convener of the APLAR systemic lupus erythematosus (SLE) special interest group (SIG).
• Dr. Mok is the senior associate editor of the International Journal of Rheumatic Diseases, Therapeutic Advances of Musculoskeletal Diseases, Frontiers in Immunology, and an editorial member of the Journal of Rheumatology, Lupus and Current Rheumatology Review.
• He is the first author of >250 papers in a number of Rheumatology and medical journals including Lancet Rheumatology, Annals of the Rheumatic Diseases, Nature Review Rheumatology, Arthritis & Rheumatology and Journal of Internal Medicine.
• The research interest of Dr. Mok is SLE, particularly lupus nephritis, and glucocorticoid induced osteoporosis.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Integrating One Health in Infectious Disease Prevention and Control" in Infection and Drug Resistance.

It is increasingly recognized that the management of infectious diseases can be improved through intersectoral or interdisciplinary collaborations. One of the most prominent examples is the development of the rabies vaccine, which first demonstrated efficacy in dogs and was later adapted as post-exposure prophylaxis in humans. In 1964, Calvin Schwabe, a distinguished veterinarian and epidemiologist, coined the term “One Medicine” in response to the separation of human and veterinary medicine. This concept was later reintroduced in the 21st century and evolved into “One Health.” Following its adoption and advocacy by public health agencies, One Health is now defined as “an integrated, unifying approach that aims to sustainably balance and optimize the health of humans, animals, plants, and ecosystems. It recognizes that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.”

Several case studies have demonstrated the public health benefits of implementing One Health principles. For instance, CIPARS (the Canadian Integrated Program for Antimicrobial Resistance Surveillance) is an integrated antimicrobial resistance surveillance network that primarily monitors enteric bacteria from humans, animals, and the environment. This program has not only informed policy development but has also led to stewardship interventions (e.g., the banning of ceftiofur use in poultry due to resistant Salmonella). Since the SARS-CoV-2 pandemic, there has been renewed interest in zoonotic diseases. To this end, a joint vaccination program for humans and animals has been piloted under the One Health framework. Despite its promise, more work is needed before One Health principles can be fully realized. One current challenge is the emergence of Aspergillus fumigatus, an environmental fungus that causes resistant invasive fungal infections and is linked to the use of dual-use antifungals in agriculture. Tackling this issue will require not only clinicians but also the agricultural sector.

In this article collection, we welcome submissions that advance our understanding of infectious diseases and their management through the broader lens of One Health, incorporating animal and environmental health. This may include fundamental research, policy proposals, and initiatives or implementation studies. Case studies, reviews, perspectives, and short communications are also welcome.

Keywords

• One Health
• Communicable Diseases
• Drug Resistance, Microbial
• Antimicrobial Stewardship
• Environmental Health

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your paper on our website, entering the promo code 2311A to indicate that the paper is intended for the Article Collection. The deadline for submitting manuscripts is 28 February 2027.

Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Aditya K. Gupta, University of Toronto, Canada

[email protected]

Dr Aditya K. Gupta is a dermatologist with about 35 years of experience and more than 900 publications. Dr. Gupta received his medical degree from the University of Southampton, UK. He completed a dermatology residency/clinical research fellowship at the University of Michigan, Ann Arbor, and has received a Ph.D. from the University of Göteborg, Sweden. He is Professor of Dermatology at the University of Toronto Temerty Faculty of Medicine. He is a Principal Investigator of the Mediprobe Research Inc., Canada. He has organized and conducted active clinical trial units in London, Ontario, and is the director of a basic research laboratory. His clinical research has focused on superficial fungal infections (onychomycosis, tinea pedis, tinea capitis), psoriasis, atopic dermatitis, acne, actinic keratosis, and skin cancer.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Non-Pharmacological Interventions for Improving Physiological, Physical, and Psychological Health Outcomes in Individuals with COPD" in the International Journal of Chronic Obstructive Pulmonary Disease.

Optimal management of COPD includes non-pharmacological interventions including pulmonary rehabilitation, smoking cessation, disease self-management, medication adherence, routine vaccinations, oxygen therapy and ventilatory support, and physical activity promotion. This Article Collection highlights new and innovative non-pharmacological interventions for improving physiological, physical, and psychological outcomes in individuals with COPD.

COPD is a leading cause of morbidity, disability, and mortality worldwide. The disease affects the whole person impacting physiological (e.g., lung function), physical (e.g., physical activity, exercise capacity), and psychological (i.e., depression) outcomes. Non-pharmacological interventions are part of guideline-based care for COPD. Yet, gaps in the management of COPD exist. Many non-pharmacological interventions are underutilized and/or benefits dwindle over time. For example, while pulmonary rehabilitation remains the gold-standard for improving an array of health outcomes, it remains severely underused and benefits begin to wane after 12 months. New and novel non-pharmacological intervention can supplement existing non-pharmacological interventions for individuals with COPD with the potential to improve physiological, physical, and psychological outcomes.

This Article Collection seeks articles focused on intervention development and testing (from preliminary/pilot to effectiveness, implementation and dissemination studies) of interventions targeting improvement in physiological, physical, and/or psychological outcomes. We welcome original research articles, short reports, and systematic reviews. Study protocols of highly innovative non-pharmacological interventions will also be considered. Interventions may include a single component (e.g., balance training) or multiple components (e.g., complex behavioral interventions). Interventions that include chronic pain management, treatment of sleep disturbances, integrative therapies such as mind-body interventions, and psychotherapies (i.e., cognitive behavioral therapy) are salient to this Article Collection. Outcomes should broadly fall within the categories of: physiological, physical, and psychological domains and may include primary and/or secondary outcomes, as well as secondary analysis of completed trials. Moderator and/or mediation analyses of completed trials asking how and for whom interventions work are also welcomed.

Keywords

• Non-pharmacological interventions
• Physiological
• Physical
• Psychological
• Outcomes

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31 July 2026.

Please submit your manuscript on our website, quoting the promo code 15402 for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Patricia M. Bamonti, VA Boston Healthcare System, Harvard Medical School, USA

[email protected]

Patricia M. Bamonti, PhD, ABPP, Assistant Professor of Psychology, Department of Psychiatry, Harvard Medical School, is a Staff Psychologist at VA Boston Healthcare System. Dr. Bamonti studies the impact of depression and anxiety symptoms on health outcomes in the context of pulmonary rehabilitation and physical activity interventions. She is currently developing and testing an integrated physical activity intervention with cognitive behavioural therapy for individuals with COPD and comorbid depression and/or anxiety.

Marilyn L. Moy, VA Boston Healthcare System, Harvard Medical School, Boston University Chobanian & Avedisian School of Medicine, USA

[email protected]

Marilyn L. Moy, M.D., M.Sc., Associate Professor of Medicine, Harvard Medical School, is a Staff Pulmonary Physician at VA Boston Healthcare System. She is Medical Director of the Pulmonary Rehabilitation Program, accredited by the American Association of Cardiovascular and Pulmonary Rehabilitation. Dr. Moy studies the role of physical activity in the risk stratification of COPD, technology-based interventions to promote PA, and the biological mechanisms underlying the beneficial effects of PA on COPD outcomes.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Relationship, Intimacy and Sexual Health in COPD: Dyadic Processes, Biopsychosocial Perspectives and Interventions" in the International Journal of Chronic Obstructive Pulmonary Disease.

Chronic obstructive pulmonary disease (COPD) is a progressive condition that impacts patients' lives far beyond respiratory impairment, limiting everyday functioning, changing identity and influencing interpersonal relationships. Increasingly, attention has turned toward how COPD influences relationship dynamics, intimacy and sexual health. These domains are central to quality of life but have historically been underexplored in respiratory research. This Article Collection seeks to advance a comprehensive understanding of how COPD intersects with relational and sexual wellbeing within a biopsychosocial framework. It emphasizes both individual and dyadic perspectives, recognizing that COPD affects not only those diagnosed but also their partners and broader relational contexts.

The topic of this Article Collection has direct implications for good patient care and patient-centered outcomes in COPD. While traditional clinical management often prioritizes physiological symptoms, evidence suggests that relational and sexual wellbeing significantly influence mental health, treatment adherence and overall quality of life. Unaddressed challenges in intimacy and partnership can contribute to social isolation, psychological distress and reduced coping capacity for both patients and partners. Conversely, supportive relationships and adaptive dyadic coping strategies can enhance resilience and facilitate adjustment to chronic illness. Despite this, healthcare systems frequently overlook these dimensions due to stigma, lack of training, or limited evidence-based guidance. By consolidating research in this area, this collection aims to inform clinical practice, promote open dialogue and support the development of interventions that address relational and sexual health as integral components of COPD care.

This Collection welcomes research spanning a broad range of topics related to relationship dynamics, intimacy, and sexual health in COPD. Relevant subtopics include but not limit to dyadic coping and adjustment, communication patterns, caregiver-partner experiences, sexual function and wellbeing, and the influence of gender and sex differences. Studies addressing diverse relationship forms – including heterosexual and same-sex partnerships – are encouraged, as are investigations focusing exclusively on partners. The collection also invites work on multimorbidity within individuals and couples, exploring how co-occurring conditions shape relational and sexual outcomes. Both descriptive and interventional research are within scope, including studies evaluating psychosocial, behavioral or clinical interventions. Submissions may include original research articles (quantitative, qualitative or mixed methods), systematic and narrative reviews, brief reports and perspectives, provided they align with the journal’s focus on COPD and contribute to advancing knowledge in this emerging and clinically relevant field.

Keywords

• Chronic respiratory disease
• Intimacy or intimate relations
• Sexual wellbeing
• Dyadic coping
• Partnership

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 31 March 2027.

Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Ingeborg Farver-Vestergaard, Lillebaelt Hospital, University of Southern Denmark, Denmark

[email protected]

Dr Farver-Vestergaard is a clinical psychologist and an associate professor in health psychology and respiratory care. She has conducted and supervised several studies within the field of sexual health and chronic respiratory conditions.

Yoon Frederiksen, Aarhus University, Aarhus University Hospital, Denmark

[email protected]

Dr Frederiksen is a clinical psychologist, certified in health psychology as well as clinical sexology. She is an associate professor in health psychology and clinical sexology.

Anders Løkke, Lillebaelt Hospital, University of Southern Denmark, Denmark

[email protected]

Prof Løkke is a respiratory physician and a professor of intersectorial research and care. He has conducted and supervised numerous clinical and epidemiological studies focusing on biopsychosocial aspects and interventions in respiratory diseases, mainly COPD.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Innovations and Integrations in regenerative medicine" in the International Journal of General Medicine.

Regenerative medicine is increasingly recognized as a central pillar of future healthcare. Unlike conventional treatments that primarily focus on managing symptoms, regenerative approaches aim to restore or replace damaged tissues and organs. This shift is particularly important as chronic diseases, degenerative conditions, and organ failure continue to increase in prevalence worldwide. Advances in stem cell biology, biomaterials, tissue engineering, gene editing, and immunomodulation are driving progress toward therapies that have the potential to provide lasting functional recovery. This Collection, "Innovations and Integrations in Regenerative Medicine" presents recent developments that demonstrate scientific discoveries and how they are being translated into clinical practice. By bringing together contributions from basic science, translational research, and clinical studies, the series highlights the potential of regenerative strategies to redefine treatment pathways and set new standards of care in modern medicine.

Regenerative medicine tackles health problems that current treatments often fail to resolve. Chronic conditions such as heart disease, diabetes, neurodegenerative disorders, and organ failure are typically managed, not cured. Regenerative approaches seek to restore the structure and function of damaged tissues and organs, directly addressing root causes rather than symptoms. This field promises to overcome critical limitations like organ transplant shortages and immune rejection by enabling growth or restoration of tissues using a patient’s own cells. It also holds cross-cutting potential for different targets, such as cardiovascular repair, neurological disorders, autoimmune diseases, and more. There are many of these therapies have already reached clinical or commercial stages, including FDA-approved treatments for wounds and orthopedic injuries, strengthening the path from research to real-world impact.

This Collection centers on regenerative medicine within the framework of internal medicine, reflecting the journal's commitment to enhancing understanding of pathogenesis, diagnosis, treatment protocols, patient outcomes, and quality of life. It invites contributions that explore areas such as stem-cell therapies, biomaterial innovations, tissue engineering, gene editing, immune modulation, and their clinical applications in cardiovascular, endocrine, neurological, and multi-system diseases. Articles that integrate basic research and clinical trials are especially welcome.

Keywords

1. Regenerative Medicine
2. Stem Cell Therapy
3. Tissue engineering
4. Biomaterials
5. Translational Medicine

All manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 9D1C8 to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is July 6 2026.

Guest Advisors

Ke Huang, Texas A&M University

[email protected]

Dashuai Zhu, Columbia University 

[email protected]

Dr. Dashuai Zhu is a biomedical researcher specializing in regenerative medicine and therapeutic biomaterials. His work focuses on engineering advanced delivery platforms to promote tissue repair and modulate immune responses. Dr. Zhu has contributed extensively to translational research, bridging innovative laboratory discoveries with clinical applications.

Panagiotis Tasoudis, UNC Hospital 

[email protected]

Dr. Panagiotis Tasoudis is a surgery resident with a strong focus on advanced cardiothoracic procedures and transplant medicine. His clinical and research interests include lung and heart transplantation, LVAD therapy, aortic disease management, and regenerative medicine. Dr. Tasoudis is dedicated to integrating surgical innovation with translational research to improve patient outcomes.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Today in Pulmonary Medicine from the Bench to Bedside and Beyond" in the International Journal of General Medicine.

The International Journal of General Medicine seeks to publish innovations in clinical, translational, and basic science that improve our knowledge and management of pulmonary diseases. Although the scope of pulmonary medicine is vast, we seek impactful contributions that use state-of-the-art approaches to promote lung health in the areas of obstructive airways disease, fibrosis, pulmonary hypertension, sleep, neural control of breathing, environmental medicine, and population health. Topics may also include new therapeutics, biomarkers, diagnostics, devices, and new research methodology.

Lung diseases represent one of the most widespread and severe categories of medical conditions globally. In the United States alone, tens of millions of people are affected by various forms of lung disease, ranging from mild respiratory issues to life-threatening conditions. These diseases include chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and lung cancer, among others. The primary causes of lung disease are well established: tobacco smoke—both firsthand and secondhand exposure—remains the leading risk factor. In addition, respiratory infections such as pneumonia and influenza can significantly damage lung function, particularly in vulnerable populations. Genetic factors also play a critical role, with inherited conditions like cystic fibrosis contributing to chronic respiratory problems. Environmental pollutants, occupational exposures, and lifestyle factors further compound the risk, making lung health a critical area of public health concern.

Article types such as Original Research, Reviews and Commentaries are welcomed. Case reports/series are not sought; any submitted to the International Journal of General Medicine will be diverted to the International Medical Case Reports Journal.

Topics of interest include but are not limited to:
Innovative pulmonary therapeutics

• Chronic obstructive pulmonary disease (COPD)
• Pulmonary hypertension
• Pulmonary fibrosis
• Genetic factors of pulmonary health
• Environmental and lifestyle factors affecting pulmonary health

Keywords

1 Respiratory
2. Lung
3. Airways
4. Fibrosis
5. Population health

All manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 5E564  to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 July 2026.

Guest Advisor

Professor Reynold A. Panettieri, Jr., MD, Rutgers University, New Brunswick, NJ USA

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Journal of Nanomedicine on "Advanced Nanomedicine Strategies for Targeted Drug Delivery and Precision Therapeutics", organized by Prof. Jonghoon Choi (Chung-Ang University, South Korea).

The field of nanomedicine has revolutionized the landscape of modern therapeutics by offering unprecedented control over the delivery of pharmaceutical agents. By utilizing engineered nanomaterials, researchers can now navigate complex biological environments to deliver drugs specifically to diseased tissues while minimizing systemic side effects. This Article Collection focuses on the latest breakthroughs in nanocarrier design, including the development of bio-responsive materials, lipid-based nanoparticles, and metallic nanostructures. We aim to explore how these platforms are being refined to improve solubility, stability, and the pharmacokinetic profiles of both small molecules and biologics.

Despite significant laboratory success, the clinical translation of nanomedicine remains a critical challenge. Understanding the interaction between nanomaterials and the biological milieu—such as the protein corona and immune system evasion—is essential for developing effective therapies. This Collection is vital because it bridges the gap between fundamental materials science and clinical application. By highlighting strategies that overcome physiological barriers, such as the blood-brain barrier or the dense stroma of solid tumors, this collection provides a roadmap for the next generation of precision medicine that can adapt to individual patient needs.

We invite submissions that cover a broad spectrum of nanomedicine applications, including but not limited to:

• Mitochondrial targeting and organelle-specific delivery.
• Stimuli-responsive drug release mechanisms (pH, temperature, or enzyme-activated).
• Nano-bio interactions and toxicity assessments.
• Scale-up and manufacturing challenges for clinical trials. We welcome Original Research articles, and Comprehensive Reviews. All manuscripts must align with the journal's scope of advancing drug delivery technology.

Please review the journal’s aims and scope and author submission instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 54176 to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 31 January 2027.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisor

Prof. Jonghoon Choi, Chung-Ang University

[email protected]

Professor Choi is a full professor at the Chung-Ang University specializing in nanomedicine and biotechnology. His research focuses on the development of advanced drug delivery systems and functional nanomaterials for therapeutic applications. He has published extensively in high-impact journals regarding the medical applications of biodegradable materials and targeted delivery platforms. He is committed to advancing the field of bioengineering through both research and academic leadership.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Journal of Nanomedicine on "Artificial Intelligence Enabled Nanotechnology for Precision Theranostics", organized by Prof. Mohamed Kchaou (University of Bisha, Saudi Arabia) and Prof. Md Faiyazuddin (ARAM Institute, India).

Artificial Intelligence (AI)-enabled nanotechnology is rapidly reshaping the design and application of advanced nanomaterials for biomedical diagnostics and drug delivery systems. The convergence of AI techniques—such as machine learning, deep learning, and predictive modeling—with functional nanomaterials (e.g., nanoparticles, nanocomposites, and stimuli-responsive systems) enables the rational design of highly efficient and adaptive healthcare solutions. This coupling between computational intelligence and material engineering facilitates precise control over physicochemical properties, targeted delivery, and real-time biological interactions. In diagnostics, AI-driven nanoplatforms enhance sensitivity and specificity through intelligent signal processing and biomarker recognition, enabling early and accurate disease detection. In parallel, AI-assisted optimization of drug loading, release kinetics, and targeting mechanisms significantly improves therapeutic outcomes while minimizing side effects. This Article Collection aims to explore recent advances at this interdisciplinary interface, highlighting how AI–nanomaterial integration is driving the development of next-generation, data-driven, and patient-centered diagnostic and therapeutic systems.

This convergence is critical as healthcare systems face increasing demands for early diagnosis, personalized treatment, and improved therapeutic efficiency. Conventional diagnostic and drug delivery approaches often suffer from limited sensitivity, poor targeting, and high variability in patient response. AI-enabled nanomaterials address these challenges by enabling data-driven design, predictive performance, and adaptive functionality at the nanoscale. This leads to faster, more accurate diagnostics and safer, more effective therapies. Ultimately, such integrated technologies have the potential to reduce healthcare costs, accelerate clinical translation, and support the transition toward precision and personalized medicine.

This Article Collection covers the development and application of AI-enabled nanotechnology, particularly nanomaterials, within the scope of nanomedicine, focusing on their roles in advanced diagnostics and targeted drug delivery. Topics of interest include:

• Design of functional nanoparticles (e.g., lipid-based, polymeric, metallic, and hybrid nanostructures),
• AI-assisted nanotechnology optimization, and intelligent nanosystems for disease detection and therapy,
• Biosensing platforms, imaging-enhanced nanodiagnostics, stimuli-responsive drug delivery, and nano–bio interactions,
• Computational modeling, data-driven design, and translational nanomedicine.

Please review the journal’s aims and scope and author submission instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 9A8F2 to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 31 January 2027.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisors

Prof. Mohamed Kchaou, University of Bisha

[email protected]

Prof. Mohamed Kchaou is a Full Professor at the University of Bisha, Saudi Arabia, and a Senior Researcher in sustainability and advanced materials. He is ranked among the Stanford–Elsevier World’s Top 2% Scientists (2025) and has received multiple awards for excellence in research, innovation, and academic leadership. He has authored more than 200 scientific contributions, including over 130 peer-reviewed journal articles, and has established a strong international collaboration network with leading universities and research centers worldwide. His research focuses on the integration of artificial intelligence with advanced nanomaterials for healthcare, energy, and circular economy applications, with a particular emphasis on AI-enabled nanomedicine and emerging technologies for societal impact.

Prof. Md Faiyazuddin, ARAM Institute

[email protected]

Prof. Md Faiyazuddin is Professor & Principal at ARAM Institute, India, and Former Dean (R&D) and Professor of Pharmaceutics at Al-Karim University. He also serves as Adjunct Professor at SIMATS and UniKL Global Research Fellow (GloRe). With over 19 years of experience across academia and industry in India and Saudi Arabia, he has held senior leadership roles, including Business Director at Nano Drug Delivery® USA. His research focuses on AI-enabled nanomedicine and advanced drug delivery systems, integrating artificial intelligence with engineered nanomaterials to develop targeted therapeutic platforms. He has authored more than 200 scientific contributions, including over 130 peer-reviewed journal articles, with over 2400 citations (h-index 25). A recipient of the DST Young Scientist and Dr. P.D. Sethi Awards, his work emphasizes translational innovation in pharmaceutical sciences.

View all papers in this article collection

We are pleased to announce a new Article Collection in the International Journal of Nanomedicine, dedicated to the game-changing role of lipid nanoparticles (LNP) in the area of mRNA Therapeutics. Since their clinical introduction, mRNA-LNP therapeutics have revolutionized patient care, offering significant benefits in speed of development, therapeutic efficacy, and targeted delivery for eligible patients.

Given the global importance of mRNA-LNP vaccines in COVID-19, and their potential for use in other infectious diseases, cancer, and genetic disorders, the International Journal of Nanomedicine is inviting submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.

The Collection, edited by Editor-In-Chief Prof. RDK Misra, will be included in Taylor and Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of LNP in mRNA therapeutics, the Editors are particularly interested in manuscripts relating to the following areas:

• Novel lipid nanoparticle formulations and characterization
• Optimization of mRNA delivery systems and targeting strategies
• Scalable manufacturing processes & stability optimization
• mRNA-based vaccines for infectious disease
• mRNA-based therapies for genetic diseases including metabolic disorders, hemophilia, and neurological conditions
• Cancer vaccines and immunotherapies

Please review the journal’s aims and scope and author submission instructions prior to submission. 

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 0BEC2 for a 20% discount on the publishing fee and to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 31 December 2026.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Medical Case Reports Journal on “Advancing Oncology through Clinical Case Reports: Insights, Challenges, and Future Directions”, organized by our Associate Editors-in-Chief Prof. Xudong Zhu from University of Kentucky, USA, and Prof. Jiawen Bu from Shengjing Hospital of China Medical University, China.

Clinical case reports in oncology provide critical insights into rare malignancies, atypical treatment responses, and novel therapeutic approaches. These reports bridge the gap between theoretical research and real-world clinical practice, offering clinicians and researchers actionable knowledge to improve patient outcomes.

This Article Collection aims to compile high-quality case studies that highlight diagnostic dilemmas, innovative therapies, and multidisciplinary management strategies in oncology.

Oncology is a rapidly evolving field where individualized patient care is paramount. Case reports serve as foundational tools for identifying emerging trends, unexpected side effects, and therapeutic breakthroughs. By documenting unique clinical scenarios, this collection will foster a deeper understanding of tumor biology, resistance mechanisms, and personalized treatment paradigms. Such knowledge is vital for advancing global cancer care and informing future clinical trials.

We invite submissions of case reports, case series, and clinical vignettes that address the following subtopics:

• Rare or underreported malignancies
• Unusual presentations or complications of common cancers
• Innovative uses of targeted therapies, immunotherapies, or combination regimens
• Ethical and logistical challenges in oncological care
• Long-term survivorship and quality-of-life considerations

All submissions must align with the journal's scope of translational and clinical research.

Please submit your manuscript on our website, using the promo code FB6C1 for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advancing Oncology through Clinical Case Reports: Insights, Challenges, and Future Directions” Collection. We will be welcoming relevant papers up until the 31st December 2026.

Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Diagnostic Dilemmas and Therapeutic Insights in Cardiovascular Case Reports", in the International Medical Case Reports Journal, organized by our Associate Editors-in-Chief Dr. Vinay Kumar from Pennsylvania State University Hershey Medical Center, USA, and Ms. Anuradha Tyagi from Institute of Nuclear Medicine & Allied Sciences, India.

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, spanning a broad spectrum of presentations, complexities, and therapeutic challenges. Case reports play a unique and indispensable role in cardiology by capturing novel presentations, rare complications, unexpected treatment responses, and innovative diagnostic approaches. This Article Collection aims to highlight clinically significant case reports that enhance our understanding of cardiovascular and vascular conditions and inform frontline clinical decision-making.

Despite rapid advances in cardiovascular medicine, clinicians continue to encounter unexpected or atypical patient scenarios. Case reports serve as valuable educational tools, offering real-world insights beyond the confines of large trials and guidelines. They often provide the first glimpse of emerging diseases, drug side effects, procedural innovations, and complex comorbidities. By systematically gathering high-quality case reports, we create a platform that promotes shared clinical learning and fosters global dialogue on rare and instructive cardiovascular phenomena.

This Article Collection invites submissions that align with the scope of Case Reports in Cardiology, focusing on all aspects of heart and vascular health. Subtopics may include - but are not limited to - ischemic heart disease, structural heart defects, electrophysiological disorders, valvular diseases, cardiomyopathies, vascular anomalies, endovascular interventions, and cardio-oncology. We welcome classical case reports, case series, clinical images, and brief communications that offer new insights, challenge existing paradigms, or prompt further investigation. Submissions should clearly articulate the educational value and clinical relevance of the case, ideally supported by imaging, histopathology, or procedural documentation where applicable.

Please submit your manuscript on our website, using the promo code 71858 for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Diagnostic Dilemmas and Therapeutic Insights in Cardiovascular Case Reports” Collection. We will be welcoming relevant papers up until the 31st December 2026. 

Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “Advances in Rhinology and Allergy: From Disease Mechanisms to Treatment Innovations” in the Journal of Asthma and Allergy.

Rhinologic and allergic disorders, such as acute/chronic rhinosinusitis, nasal polyposis, allergic/non-allergic rhinitis etc., frequently cause physical and mental illness. Despite the rapid progress of medicine, some rhinologic disorders remain complex and have a significant impact on the global economy in the modern era.

Early detection and proper management of the rhinologic disorders based on disease mechanisms deserve further attention. Advances in disease mechanisms and treatment innovations would provide practical information about precise medicine and prediction in response to medical or surgical therapy and are therefore pivotal.

This Article Collection aims to highlight recent advances in the disease mechanisms and treatment innovations in rhinology and allergy. Rapid progress in basic science, translational medicine, and biomedical technology has significantly improved our understanding of the pathophysiology underlying rhinologic and allergic disorders. We invite authors to submit original research articles, reviews, and clinical studies that investigate the molecular and cellular mechanisms of diseases in rhinology and allergy, as well as innovative diagnostic and therapeutic methods.

Keywords

• Chronic rhinosinusitis
• Rhinitis
• Allergy
• Nasal surgery
• Pathophysiology

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31 December 2026.

Please submit your manuscript on our website, quoting the promo code 4F6E6 to indicate the paper is intended for consideration in the Article Collection.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Please be sure to select the appropriate Article Collection from the drop-down menu in the submission system.

Guest Advisor

Professor Chien-Chia Huang, Division of Rhinology, Department of Otolaryngology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

[email protected]

Prof. Chien-Chia Huang is associate professor of Division of Rhinology, Department of Otolaryngology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. He also serves as director of the Division of Paediatric Otolaryngology. He obtained his degree in Medicine at the University of Chang Gung University (Taiwan). His PhD was issued by the University of Chang Gung University. His main research interests are the rhinologic and allergic diseases, including chronic rhinosinusitis, rhinitis, and obstructive sleep apnea.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Bone-Immune System Crosstalk in Musculoskeletal Health and Disease", in the Journal of Inflammation Research.

Acute inflammation is a fundamental reparative response to injury in musculoskeletal tissues, orchestrating the recruitment of immune cells and the coordinated activity of osteoblasts, osteoclasts, and chondrocytes to remodel and restore damaged bone and cartilage. This intricate process is governed by a sophisticated network of immune signaling pathways and immunometabolic cues, maintaining a delicate homeostatic balance. The emerging field of osteoimmunology is dedicated to deciphering this critical crosstalk.

A bidirectional and dynamic dialogue between hematopoietic immune cells and resident skeletal cells is essential for effective tissue repair and the maintenance of musculoskeletal health. Disruption of this communication—whether by genetic predisposition, chronic inflammation, metabolic dysfunction, or pathogen invasion—can tip the balance from regenerative healing to pathological tissue destruction. This dysregulation lies at the heart of numerous debilitating conditions, leading to chronic pain, loss of function, and significant morbidity, underscoring an urgent need for deeper mechanistic understanding.

The goal of this Article Collection is to bring to light the pivotal role that bones and the musculoskeletal system play in health and disease, and the translational implications of osteoimmunology, immunometabolism, and inflammation-mechanobiology. Key topics include, but are not limited to:

• Coordination of inflammatory processes and skeletal/immune cells involved in bone tissue repair
• Conditions such as osteoarthritis and osteoporosis, characterized by inflammation and destruction of bone and cartilaginous tissue
• Bone and joint infections such as septic arthritis and osteomyelitis
• Arthritic conditions such as rheumatoid arthritis, spondyloarthritis (including ankylosing spondylitis), and gout/gouty arthritis

Keywords

• Osteoimmunology
• Bone-Immune Crosstalk
• Musculoskeletal Inflammation
• Arthritis
• Bone tissue repair

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting a manuscript is 1 February 2027.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Dr. Chen Yan, The First Affiliated Hospital of Guangxi Medical University

[email protected]

Dr. Yan Chen is an orthopedic surgeon and Associate Editor of the Journal of Inflammation Research. His research focuses on osteoimmunology, bone regeneration, and mechanobiology of the bone marrow microenvironment. He has led multiple translational research projects exploring bone–immune interactions in musculoskeletal diseases and serves as a reviewer and editor for several international journals. His work integrates clinical orthopedics with cutting-edge molecular and spatial technologies to advance understanding of skeletal inflammation and repair.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Microbiome-Immune Crosstalk: Mechanisms, Therapeutic Modulation, and Translational Strategies in Chronic Inflammatory and Infectious Diseases", in the Journal of Inflammation Research.

The human microbiome, encompassing the diverse communities of bacteria, viruses, fungi, and other microorganisms inhabiting our body, plays a pivotal role in maintaining immune homeostasis and influencing disease outcomes. Emerging evidence has revealed that the intricate crosstalk between the microbiome and the immune system critically shapes host responses to infection, inflammation, and cancer. Dysbiosis, or imbalance in microbial communities, has been linked to chronic inflammatory diseases, autoimmune disorders, impaired wound healing, and variable responses to immunotherapies.

Understanding the mechanisms underlying microbiome-immune interactions is essential for developing innovative therapeutic strategies. Targeted modulation of microbial communities, whether through probiotics, prebiotics, postbiotics, or fecal microbiota transplantation, offers promising opportunities to enhance immune function and improve patient outcomes. Moreover, advanced multi-omics approaches are enabling a deeper understanding of host–microbe signaling pathways, revealing potential biomarkers and translational targets for precision medicine.

The interplay between the microbiome and the immune system is fundamental to human health, influencing everything from infection susceptibility to chronic inflammation and response to therapy. Dysregulation in this crosstalk can drive disease progression, reduce treatment efficacy, and contribute to poor clinical outcomes. By understanding these interactions, researchers can identify novel therapeutic targets, develop microbiome-based interventions, and enhance the effectiveness of immunotherapies.

Addressing microbiome-immune crosstalk is particularly important for precision medicine, as it enables the tailoring of treatments based on an individual’s microbial and immune profile. This approach has the potential to revolutionize the management of chronic inflammatory diseases, infectious conditions, autoimmune disorders, and cancer, ultimately improving patient outcomes and reducing healthcare burdens.

This Collection welcomes high-impact original research, reviews, mini-reviews, perspectives/commentaries, methodology papers and graphical reviews/visual communications focusing on the diverse scientific and translational innovations microbiome-immune signaling. Key themes include, but are not limited to:

1. Mechanistic insights into microbiome–immune system interactions;

2. Gut–organ axes and systemic immune regulation;

3. Microbiome influence on immunotherapy efficacy and vaccine response;

4. Dysbiosis-driven chronic inflammatory and autoimmune diseases;

5. Host–microbe signaling pathways as therapeutic targets;

6. Microbiome-targeted interventions: probiotics, prebiotics, postbiotics, and fecal microbiota transplantation (FMT);

7. Multi-omics approaches to study microbiome–immune networks;

8. Translational and clinical studies leveraging microbiome modulation.

Keywords

1. Microbiome–Immune Crosstalk

2. Dysbiosis

3. Immunomodulation

4. Chronic Inflammatory Disease

5. Precision Medicine

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, using the promo code E6AEE to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 16 November 2026.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr. Vinay Kumar, Penn State University, College of Medicine, 500 University Dr, Hershey, PA-17033, USA

[email protected]

Dr. Vinay Kumar is a Researcher (junior faculty) at the Heart and Vascular Institute, Pennsylvania State University, where his work focuses on dissecting dysregulated innate and adaptive immune networks in myocardial infarction (MI) and chronic heart failure (HF). His research emphasizes understanding the roles of distinct T-cell subsets and the time-dependent phenotypic shifts these cells undergo during chronic HF. Additionally, Dr. Kumar is dedicated to developing innovative immunomodulatory strategies to reverse pathological immune alterations and facilitate their translation from bench to bedside.

Dr. Anuradha Tyagi, Department of cBRN, Institute of Nuclear Medicine & Allied Sciences, Delhi 110054, India

[email protected]

Dr. Anuradha Tyagi is a biomedical researcher specializing in inflammation biology, wound healing, and host–pathogen interactions. Her work demonstrates that timely modulation of the inflammatory phase is crucial for proper wound closure and tissue repair, particularly in conditions like radiation dermatitis. She has highlighted the therapeutic potential of secondary bile acids in chronic wound management, showing their ability to inhibit biofilm formation, neutralize bacterial virulence factors, modulate pro-inflammatory cytokines, and promote angiogenesis. Dr. Tyagi’s research advances our understanding of immune responses, microbial dynamics, and tissue regeneration, with important translational implications for chronic wound therapy.

Dr Yash Gupta, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA-17033, USA

[email protected]

Dr. Yash Gupta is a leading translational researcher specializing in gut–liver axis disorders, with a primary focus on precision probiotics and endotoxemia in non-alcoholic fatty liver disease (NAFLD). His work includes the development of novel lipid membrane–camouflaged biomimetic nanoparticles for microRNA delivery to intestinal epithelial cells, enabling targeted therapeutic modulation of intestinal tight junction integrity. Dr. Gupta has also conducted seminal studies on microRNA-mediated suppression of kisspeptin receptors in pancreatic cancer, elucidating how comorbidities such as obesity and hypertension influence tumor survival. He has contributed to defining the role of Bifidobacterium bifidum–PPAR-γ signaling pathways, advancing probiotic-based strategies for inflammatory bowel disease. Additionally, Dr. Gupta has served as a key collaborator in multi-institutional research initiatives, including investigations into erythropoietin signaling in vagus nerve Schwann cells and its role in restoring intestinal motility following surgical injury.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Multi-Layered Regulation of Inflammation: Integrating Non-Coding RNAs, Epigenomics, Single-Cell, and Spatial Transcriptomics", in the Journal of Inflammation Research.

Inflammation is a critical physiological response, yet its dysregulation underlies numerous pathologies, including autoimmune diseases, metabolic disorders, cancer, and cardiovascular disorders. Traditional approaches to understanding inflammatory mechanisms have proven insufficient to capture the complexity of this multifaceted process. Recent advances have revealed that inflammation is orchestrated through multiple interconnected regulatory layers, extending far beyond protein-coding genes. Non-coding RNAs, including microRNAs and long non-coding RNAs, serve as crucial post-transcriptional regulators of inflammatory responses. Simultaneously, epigenomic modifications establish the chromatin landscape that governs gene accessibility and expression patterns. Single-cell transcriptomics has revolutionized our ability to dissect cell-type-specific inflammatory signatures, while spatial transcriptomics preserves the critical tissue context lost in traditional profiling methods. Finally, network-based regulatory analysis and integration of various multi-omics approaches will present a broad picture of the various mechanisms of regulation of inflammation with various associated pathologies.

This Article Collection invites contributions integrating these complementary approaches to elucidate novel regulatory mechanisms governing inflammation. By synthesizing insights across genomic, epigenomic, and cellular levels, we aim to advance understanding of inflammatory biology and identify therapeutic targets for intervention.

Understanding the multi-layered regulation of inflammation is essential for advancing precision medicine and developing targeted therapeutics. Current inflammatory disease treatments often lack efficacy due to our incomplete understanding of disease mechanisms at the molecular level. By integrating non-coding RNAs, epigenomics, single-cell, and spatial transcriptomics, we can uncover previously hidden regulatory networks controlling inflammatory responses.
This integrated approach addresses critical knowledge gaps: how non-coding RNAs fine-tune inflammatory gene expression, which epigenetic modifications drive pathological inflammation, and how cell-type-specific and tissue-specific contexts influence inflammatory outcomes. Such insights are vital for identifying biomarkers for disease stratification, predicting treatment response, and discovering novel drug targets.

Furthermore, this multi-modal integration reflects the reality of biological systems, where regulation operates simultaneously across multiple layers. Publications from this special call will establish a new paradigm for inflammatory research, bridging computational and experimental methodologies to translate discoveries into clinical benefits for patients with inflammatory and immune-mediated diseases.

This Article Collection delves into inflammation, which is governed by complex, multi-layered regulatory mechanisms spanning microRNA, transcriptional, post-transcriptional, epigenetic, and spatial transcription, etc. Emerging integrative approaches combining non-coding RNA biology, epigenomics, single-cell, and spatial transcriptomics are reshaping our understanding of immune regulation and disease pathogenesis.

Potential Subtopics:
• Functional roles of microRNAs, long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) in modulating inflammatory signalling pathways, including their impact on cytokine production, immune cell activation, and feedback regulation in acute and chronic inflammation.
• Epigenomic regulation of inflammation, focusing on DNA methylation, histone modifications, chromatin accessibility, and 3D genome organization that influence immune gene expression and cellular memory in inflammatory diseases.
• Single-cell transcriptomic and multi-omic profiling to dissect immune cell heterogeneity, lineage trajectories, and dynamic responses during inflammation, infection, and tissue injury.
• Spatial transcriptomics to map cellular interactions and microenvironmental niches within inflamed tissues, enabling localization of immune responses and identification of tissue-specific regulatory circuits.
• Integrative computational frameworks and multi-omics approaches to reconstruct regulatory networks, identify biomarkers, and uncover therapeutic targets in complex inflammatory disorders.

Keywords

1. Inflammation Regulation
2. Non-Coding RNAs
3. Epigenomics
4. Single-Cell Transcriptomics
5. Spatial Transcriptomics

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting a manuscript is 1 March 2027.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr. Swarna Kanchan, Joan C. Edwards School of medicine, Marshall University: Huntington, West Virginia, US

[email protected]

Dr. Swarna Kanchan is associated with Joan C. Edwards School of Medicine, Marshall University, Huntington, West Virginia, USA. He has published several peer-reviewed research articles, review articles, book chapters, and books with international publishers. He is a peer reviewer and editorial board member of international scientific journals and committees. He has delivered invited lectures and attended various conferences and workshops at national and international institutions in India, France, Germany, Switzerland, Poland, and the United States of America.

Dr. Minu Kesheri, Joan C. Edwards School of Medicine, Marshall University: Huntington, West Virginia, US

[email protected]

Dr. Minu Kesheri is associated with Joan C. Edwards School of Medicine, Marshall University, Huntington, West Virginia, USA. She has high-impact peer-reviewed international publications, including research articles, review articles, book chapters, and books. She is a peer reviewer and editorial board member of international scientific journals and committees. She has delivered invited lectures, participated in various conferences and workshops at national and international institutions in India, France, Germany, Switzerland, Poland, and the United States of America.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "The Role of Aseptic Inflammation in Cholestatic and Ischemic Liver Injury: From Diagnosis to Regenerative Therapy", in the Journal of Inflammation Research.

Aseptic (sterile) inflammation, defined as the immune response to non-infectious stimuli, is gaining increasing importance in the pathogenesis of liver diseases. Particularly in cholestatic and ischemic liver injury, damage-associated molecular patterns (DAMPs) released following cellular damage initiate inflammatory processes through activation of the innate immune system and play a decisive role in disease progression.

Although liver and gallbladder inflammation is often associated with infections (viral hepatitis, cholangitis) or autoimmune processes, aseptic inflammation (sterile inflammation) is gaining increasing importance in clinical practice. Ischemia-reperfusion injury (IRI), extrahepatic cholestasis (bile duct obstruction), or toxic drug injury can trigger a potent inflammatory response in the absence of pathogens. This process can lead to hepatocyte death, impaired bile duct remodeling (ductopenia), and ultimately fibrosis or failure.

This Article Collection aims to comprehensively address the mechanistic role of aseptic inflammation in cholestatic liver diseases (e.g., primary biliary cholangitis and primary sclerosing cholangitis) as well as in ischemic liver injury. By integrating basic science findings with clinical practice, the Collection seeks to offer new perspectives in the areas of diagnosis, prognosis, and treatment, while providing an interdisciplinary platform for researchers working in the fields of hepatology, immunology, transplantation, and intensive care. Particularly through the combined evaluation of translational research, experimental models, and clinical studies, it will contribute to the development of innovative treatment strategies targeting aseptic inflammation as well as also diagnostic tools and therapeutic approaches that can be directly translated into clinical practice, thereby guiding future research in the field of liver and gallbladder inflammation. We will consider any article type accepted by the journal, with special attention given to original research, reviews, brief reports, and perspectives/opinion pieces.

Within the scope of this collection, the following themes are particularly encouraged:

1. Molecular and Cellular Mechanisms of Aseptic Inflammation
- DAMPs and pattern recognition receptors (TLRs, NLRs)
- Inflammasome activation (especially NLRP3)
- Oxidative stress and mitochondrial dysfunction
- Cell death mechanisms (apoptosis, necroptosis, pyroptosis)
- Cytokine Networks involved in pathogenesis of aseptic inflammation

2. Cholestatic Liver Diseases
- Bile acid-mediated inflammation and toxicity
- Immune response in primary biliary cholangitis and primary sclerosing cholangitis
- Hepatocyte and cholangiocyte injury in cholestasis

3. Ischemic and Ischemia-Reperfusion Injury
- Inflammatory response following transplantation and surgery
- Microcirculatory disturbances
- Immune cell activation (Kupffer cells, neutrophils)

4. Diagnostic Approaches and Biomarkers
- Non-invasive markers of inflammation
- Multi-omic approaches (genomics, proteomics, metabolomics)
- Assessment of inflammation using imaging techniques

5. Fibrosis and Regeneration
- Inflammation–fibrosis interplay
- Hepatic stellate cell activation
- Liver regeneration and tissue repair

6. Therapeutic and Regenerative Approaches
- Inflammasome inhibitors and immunomodulation
- Bile acid receptor-targeted therapies (FXR, TGR5)
- Cellular therapies and regenerative medicine
- Experimental and clinical novel treatment strategies

Keywords

1. Aseptic inflammation (Sterile inflammation)
2. Cholestatic liver diseases
3. Ischemia-reperfusion injury
4. Inflammasome activation
5. Liver regeneration

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting a manuscript is 1 March 2027.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Dr. Fatih Türker, Haseki Training And Research Hospital

[email protected]

Dr. Fatih Türker serves as an Associate Professor at the Department of Internal Medicine, Istanbul Haseki Training and Research Hospital, University of Health Sciences. In 2015, he completed his MD degree in Internal Medicine at Istanbul Haseki Training and Research Hospital. As a clinician and educator, Dr. Türker is dedicated to patient care, medical education, and scientific research. His responsibilities include comprehensive patient evaluation, diagnosis and management of multisystem diseases, clinical research, and supervising the training of new internal medicine specialists. He holds memberships in various national and international professional societies. His research interests encompass a wide range of topics, including chronic liver diseases, post-liver transplantation patient follow-up and evaluation, fatty liver disease, diabetes mellitus and its complications, causes of mortality in hospitalized internal medicine patients, and the impact of various inflammation and nutrition indices on mortality. He has published numerous articles in national and international journals and serves as a voluntary peer reviewer for esteemed national and international publications, contributing to the evaluation of numerous manuscripts.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "A Multidisciplinary Approach to Reducing Suicide Risk Among Adolescents: Strategies, Challenges, and Solutions", in the Journal of Multidisciplinary Healthcare.

Youth suicide is a pressing crisis today. Globally, the World Health Organization (WHO) reported that more than 720,000 people die each year by suicide, and suicide is now the third leading cause of death among 15–29 year olds (WHO, 2025). Over the past decade, youth trends have shown a sharp increase. In the United States, the suicide rate for 10–14-year-olds tripled between 2007–2018 before plateauing; for 15–19-year-olds, the rate rose ~57% (2009–2017) and remained high through 2021. These figures underscore that risk is no longer sporadic, but rather a persistent pattern in the current generation of adolescents (Centers for Disease Control and Prevention, 2024).

Current social and digital changes are shaping a risk ecology directly relevant to adolescent suicide. Near-constant internet exposure and increasingly widespread smartphone ownership are altering daily rhythms, reducing sleep quality and duration, and increasing exposure to harmful content, including cyberbullying, glorification of self-harm, and negative social comparison. Sleep disturbances, loneliness, and distorted self-esteem are strong predictors of suicidal ideation and self-harm behavior, so an intensification of these factors in adolescents should be considered a driver of increased risk. At the same time, reduced face-to-face interactions with peers and decreased community participation weaken traditionally protective support networks. The loss of meaningful connections diminishes adolescents’ sense of belonging and heightens perceived helplessness, two psychosocial mechanisms known to contribute to suicide ideation and attempts. The migration of interactions to digital spaces can also delay help-seeking and reduce opportunities for early detection by parents, teachers, and health professionals, while content distribution algorithms have the potential to amplify exposure to risky material among vulnerable groups.

Preventing suicide in adolescence is crucial because of its profound consequences for individuals, families, and society as a whole. Timely and evidence-based interventions can reduce risk factors, strengthen protective mechanisms, and ultimately save lives. In addition to alleviating psychological and social burdens, effective prevention strategies contribute to the development of healthier communities and reduce long term strain on healthcare systems. Multidisciplinary collaboration that brings together psychiatry, psychology, education, social work, public health, and policy studies offers the most comprehensive path toward sustainable solutions.

This Article Collection welcomes contributions that present innovative strategies, address current challenges, and propose solutions to reduce suicide risk among adolescents from a multidisciplinary perspective. Submissions may include empirical studies, systematic reviews, policy analyses, and practice-based insights.

• Relevant subtopics include, but are not limited to:
• Early detection and screening
• School- and community-based interventions
• The role of digital technologies
• Cultural and socioeconomic dimensions
• Ethical considerations in prevention programs

By integrating diverse approaches, this Collection aims to advance scholarly knowledge, foster collaboration, and support the development of effective strategies for safeguarding adolescent mental health.

References

1. Centers for Disease Control and Prevention. (2024). Youth Risk Behavior Survey (YRBS) data summary & trends report: 2013–2023. https://www.cdc.gov/yrbs/dstr/pdf/YRBS-2023-Data-Summary-Trend-Report.pdf

2. WHO. (2025). Suicide. https://www.who.int/news-room/fact-sheets/detail/suicide/

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 November 2026.

Please submit your manuscript on our website, quoting the promo code 33EF1 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors

Mr. Rohman Hikmat, Prince of Songkla University, Indonesia

Prof. Iyus Yosep, Universitas Padjadjaran, Indonesia

View all papers in this article collection

The Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Contemporary Multidisciplinary Strategies in Cardiovascular and Internal Medicine From Early Detection to Advanced Intervention".

Contemporary healthcare increasingly requires multidisciplinary strategies to address the growing complexity of cardiovascular and systemic diseases. Advances in diagnostic technology, medical therapy, interventional procedures, and integrated clinical care have transformed the management of patients from early detection to advanced intervention. In particular, the collaboration between cardiology, internal medicine, radiology, critical care, and other healthcare disciplines plays a crucial role in improving diagnostic accuracy, optimizing treatment decisions, and enhancing patient outcomes across diverse clinical settings.

This topic is important because cardiovascular disease and chronic medical conditions remain leading causes of morbidity and mortality worldwide. Early identification of disease, appropriate risk stratification, and timely intervention require coordinated efforts among multiple specialties supported by modern imaging, laboratory evaluation, and evidence-based clinical pathways. Multidisciplinary care models have been shown to improve efficiency, reduce complications, and provide more personalized treatment, especially in complex patients with multiple comorbidities. As healthcare systems continue to evolve, there is a growing need for research that integrates clinical expertise, technological innovation, and collaborative decision making.

This Article Collection welcomes original research, reviews, clinical studies, and perspectives related to multidisciplinary approaches in cardiovascular and internal medicine. Topics of interest include, but are not limited to:

• Cardiac imaging
• Preventive cardiology
• Heart failure
• Coronary artery disease
• Structural heart disease
• Critical care
• Multimodality diagnostics
• Digital health
• Artificial intelligence in healthcare
• Integrated care pathways
• Collaborative clinical management

Submissions addressing translational research, real world clinical practice, and innovations that improve patient outcomes within multidisciplinary healthcare are particularly encouraged.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 February 2027.

Please submit your manuscript on our website, quoting the promo code 78BF5 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisor 

Dr. Ricardo Adrian Nugraha, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

View all papers in this article collection

The Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Global Advances in Pharmacogenomics: From Discovery to Clinical Implementation and Improved Patient Outcomes".

Pharmacogenomics has emerged as the primary driver of treatment individualization, moving beyond a "one-size-fits-all" approach to a model where drug selection and dosages are tailored to an individual’s genetic profile. While the field has seen rapid growth in identifying genetic variants that influence drug-metabolizing enzymes and drug targets, the focus is now shifting toward the practical integration of these findings into routine healthcare. This Article Collection explores the full spectrum of PGx, from foundational variability studies to the latest in diagnostic methodologies.

The importance of this topic lies in its potential to bridge the gap between genomic discovery and clinical utility. By optimizing therapeutic efficacy and minimizing adverse drug reactions (ADRs), pharmacogenomics serves as a critical tool for improving patient safety and healthcare cost-effectiveness globally. Understanding the genetic diversity across different populations is essential to ensure that the benefits of personalized medication management are equitable and scientifically sound for all patients.

Specific Topics of Interest include:

• Clinical Utility: Real-world evidence of PGx-guided therapy in specialties such as oncology, cardiology, and psychiatry.
• Testing Methodologies: Development and validation of innovative, scalable, or cost-effective pharmacogenetic testing platforms.
• Genetic Variability: Studies on the prevalence and impact of polymorphisms in drug-metabolizing enzymes and transporters across diverse global populations.
• Implementation Science: Strategies for integrating PGx into clinical workflows, including electronic health record (EHR) integration and clinical decision support.
• Policy and Ethics: Ethical, legal, and social implications (ELSI), along with policy recommendations for national healthcare systems
• Medication Safety & ADR Management: The role of multidisciplinary teams in monitoring and preventing adverse drug reactions as a foundation for personalized therapy.

This Article Collection seeks to highlight the essential multidisciplinary collaboration between clinical pharmacists, physicians, molecular biologists, and bioinformaticians required to move pharmacogenomics from theory to practice. We invite submissions that demonstrate how integrated healthcare teams utilize genetic data to optimize therapeutic outcomes and patient safety across diverse clinical settings. The Collection particularly welcomes Original Research, Reviews, Clinical Trial Reports, Methodologies, Perspectives, and Expert Opinions that provide robust evidence for implementation. Systematic Reviews that synthesize current knowledge of genetic variability and its clinical implications are also highly encouraged.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31 December 2026.

Please submit your manuscript on our website, quoting the promo code 21442 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Meet the Guest Advisor
Dr. Mohamed Nagy is a clinical pharmacogenomics expert with extensive experience in research, teaching, and clinical practice. He is the Pharmacy Director at the Children's Cancer Hospital Egypt (CCHE) 57357, where he also founded and heads the Personalized Medication Management Unit. Dr. Nagy's research interests lie in pharmacogenomics, particularly in the application of genetic information to optimize drug therapy in pediatric oncology patients. Dr. Nagy serves on the board of the African Pharmacogenomics Network and is the chair of the global committee of the Pharmacogenomics Global Research Network.

The Guest Advisors declare no conflict of interest regarding this work.

View all papers in this article collection

The Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Multidisciplinary Advances in Nuclear Medicine for Non-Communicable Diseases".

Non-communicable diseases (NCDs), including cancer, cardiovascular, metabolic, respiratory, and neurodegenerative disorders, remain leading causes of global morbidity and mortality. Addressing these conditions requires integrated, multidisciplinary approaches that combine clinical medicine, imaging sciences, pharmacology, data science, and healthcare systems.

Nuclear medicine plays a pivotal role within this framework by enabling precise diagnosis, risk stratification, treatment planning, and response assessment. Advances in molecular imaging and theranostics increasingly support collaboration between oncologists, cardiologists, neurologists, radiologists, medical physicists, radiochemists, and allied health professionals, facilitating more coordinated and patient-centered care.

This Article Collection focuses on the multidisciplinary applications of molecular imaging and targeted radionuclide therapy in NCDs, highlighting how cross-disciplinary integration improves diagnostic accuracy, therapeutic decision-making, and clinical outcomes. Emphasis is placed on clinically translatable research, quantitative imaging, and innovations that bridge laboratory science and real-world healthcare delivery.

Topics of interest include:

• Molecular imaging in cardiovascular and metabolic diseases
• Targeted radionuclide therapy in oncology and integrated cancer care
• Neuroimaging approaches in neurodegenerative and psychiatric disorders
• Musculoskeletal and rheumatologic imaging in clinical practice
• Renal imaging and systemic disease assessment
• Radiotracer development and translational research
• Multidisciplinary care pathways, health systems integration, and global trends

We welcome original research, reviews, perspectives, and commentaries that demonstrate clear multidisciplinary relevance.

Please submit your manuscript on our website. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 1 March 2027.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors

Dr. Ahmed Saad Abdlkadir, Baghdad Radiotherapy and Nuclear Medicine Hospital, Iraq

Prof. Dr. Akram Al-Ibraheem, King Hussein Cancer Center, Jordan

View all papers in this article collection

The Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Next-Generation Vaccines and Innovative Drug Delivery Systems: From Development to Public Health Impact".

Vaccines are widely recognized as a pillar of public health, saving millions of lives annually by preventing infectious diseases and contributing to herd immunity. Recently, vaccines have experienced significant growth with the advancements in nanotechnology and vaccine technologies, including mRNA vaccines, viral vector platforms, and recombinant protein vaccines. Especially with the approval of mRNA LNP vaccine for COVID 19, research in vaccines has shifted to the development of mRNA-based vaccines with the aid of lipid nanoparticle delivery systems. Innovations in delivery technologies, including microneedle patches, intranasal delivery, and lipid nanoparticles, have revolutionized the way vaccines are administrated and stored. These advances shift the trend of conventional vaccines toward designing more efficient, precise, and patient-friendly immunization systems.

These developments are critically important in overcoming the challenges of designing the vaccine delivery systems, administration, and addressing concerns related to vaccine hesitancy faced by public health. Global experiences with pandemics, emerging infectious diseases, and persistent inequity in vaccine access have underscored the need for scalable, acceptable, and reliable vaccination strategies. However, there are increasing reports on vaccines acceptance, hesitancy, perspectives from the public, and observations from vaccinated populations, and these are highly important apart from focusing solely on advancements in vaccines development. Hence, understanding practical concerns about vaccines from a public health point of view and integrating emerging innovations with practical implementation is of utmost importance.

This Article Collection provides a multidisciplinary platform for research spanning vaccine development, delivery technologies, and their broader public health implications. It bridges the gaps between innovations in vaccine development and delivery technologies and their implication in public health, ultimately supporting more effective and accessible vaccination programs worldwide.

We welcome original research articles, reviews, and short communications regarding (but not limited to):

• Development and optimization of next-generation vaccines, e.g., mRNA vaccines, DNA vaccines, siRNA vaccines, viral vectors, and protein subunit vaccines
• Design and evaluation of innovative vaccine delivery systems and adjuvant technologies
• Stability, storage, and cold chain considerations for advanced vaccine formulations
• Alternative routes of administration, including mucosal and transdermal delivery
• Safety profiles, immunogenicity, and effectiveness of vaccines
• Public perception, vaccine hesitancy, and acceptance of vaccines
• Implementation challenges and strategies in low- and middle-income countries
• Policy, equity, and global access to vaccines

Please submit your manuscript on our website. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 28 February 2027.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors

Dr. Geetha Vaskuri, University of Kansas, USA

Dr. Nagavendra Kommineni, Thermo Fisher Scientific Inc., USA

View all papers in this article collection

The Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Strengthening Multidisciplinary Healthcare Teams: Workforce Integration, Team Collaboration, and Equitable Care".

Multidisciplinary healthcare increasingly depends on teams composed of professionals with different cultural, linguistic, educational, and lived-experience backgrounds. These differences shape how teams communicate, make decisions, collaborate, and partner with patients and families. This Article Collection explores how healthcare organizations and teams can strengthen workforce integration and team collaboration to support safer, higher-quality, and more equitable care across primary, acute, community, and long-term care settings.

This topic is important because workforce shortages, migration, and cross-border recruitment are reshaping health systems worldwide. Many services increasingly rely on internationally educated health professionals, multilingual teams, and new forms of task-sharing. Without adequate preparation and support, teams may face communication breakdowns, role ambiguity, inequitable opportunities, and reduced psychological safety, affecting staff wellbeing and patient outcomes. Source countries may also experience workforce depletion, service gaps, disrupted team functioning, and loss of training investments. Better evidence is needed on how organizations can support ethical recruitment, effective workforce integration, language access, mutual learning, and sustainable workforce partnerships.

We invite submissions on strengthening multidisciplinary healthcare teams, with particular interest in:

1. Workforce integration and ethical recruitment, including the integration of internationally educated health professionals and impacts on source-country systems and teams;

2. Language access, language discordance, and communication practices; and

3. How cultural competence, cultural humility, inclusive leadership, and diversity management influence team collaboration, staff experience, patient safety, and equitable care.

Cross-cutting topics include organizational readiness, implementation strategies, policy, and measurement. We welcome original research, mixed-methods studies, implementation and quality improvement studies, policy analyses, and systematic, scoping, or realist reviews.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 February 2027.

Please submit your manuscript on our website, quoting the promo code 983A7 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisor

Assistant Prof. Dr. Helena Kristina Halbwachs, University for Applied Sciences, Vienna, Austria

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advancing Inclusion in Pediatric Pain Research, Training, and Practice", in the Journal of Pain Research.

Much of our current understanding of pediatric pain mechanisms and interventions is informed by an evidence base that does not adequately reflect the broader population of youth living with acute and chronic pain. Individuals who are marginalized due to sociocultural characteristics including (but not limited to) racialized identity, ethnicity, indigeneity, age, sex, gender identity, disability status, educational attainment, socioeconomic position, immigration and refugee status, and geographic location are underrepresented in pain research. These same groups are also at highest risk for experiencing profound inequities in pain care and outcomes. 

Numerous calls to action have been made to improve inclusion in the design, conduct, reporting, and dissemination of pain research. Alongside efforts to meaningfully engage communities in research and recruit and retain diverse study participants, these calls highlight the importance of diversifying the research environment itself to accelerate translation of findings to real-world efforts to alleviate pain for all youth. Additionally, culturally aware mentoring resources and training for providers in culturally attuned, evidence-based pain care are imperative to foster the talents of trainees from diverse backgrounds and adequately prepare the next generation of pain scientists and clinicians. Ultimately, inclusive pediatric pain research, training, and practice seeks to ensure that innovations in pain science and care meet the needs of all youth with pain and their families. 

This Article Collection seeks to advance this cause by highlighting inclusive approaches to pediatric pain research, training, and practice. Articles that focus on underrepresented groups (e.g., infants, young adults, indigenous populations, people of color, people with disabilities, LGBTQ2A+), biopsychosocial risk and resilience factors associated with chronic primary or secondary pain in young people, use of innovative methodologies or technologies to improve the quality and equity of pediatric pain care, projects that exemplify community engagement in knowledge production and/or mobilization, and approaches to enhancing diversity and inclusion within pediatric pain research and clinical workforce are especially welcome.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 15 September 2026.

Please submit your manuscript on our website, quoting the promo code KQQFZ for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors 

Aimee Hildenbrand, Nemours Children’s Health, USA

Shreela Palit, Nemours Children’s Health, USA

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Nanotechnology, Science and Applications on "Current Advances in Nanotechnology: Prospects and Challenges of Nanotherapeutics in Treating Cancers", organized by Prof. Veena Agrawal (University of Delhi, India).

Cancer is a major health issue globally, with an estimated 20 million new cases and 9.7 million deaths in 2022. By 2050, projections indicate a significant increase to over 35 million new cases. Discovering novel medicines is an urgent need. Nanomedicine has emerged as a new multidisciplinary field capturing the attention of scientists. Nanotherapeutics have capabilities for effectively transporting medicines or gene fragments to tumor tissues via passive or active targeting processes; thus there are immense possibilities for enhancing treatment outcomes while causing minimum harm to healthy tissues. Nanoparticles can also be employed for advanced imaging techniques, such as MRI and PET scans, providing better visualization of internal organs and tissues. The engineered nanoparticles can be employed as contrast agents in cancer diagnostics to enable high sensitivity and high-resolution imaging examinations and tumor detection. Novel approaches for tumor labeling and detection are also made possible by the use of nanoprobes. While nanotechnology shows great potential, clinical translation faces challenges related to biocompatibility, toxicity, and the complexity of the tumor microenvironment.

Nanotechnology holds great potential where it enables targeted drug delivery, development of nano-biosensors for early disease detection, and advanced imaging techniques such as MRI and PET scans. Nanoparticles can be designed for improved cancer detection, and enhanced immune responses. Nanoparticles can be employed in the context of radiation sensitization and photothermal therapy to enhance the therapeutic efficacy of malignant tumors. The combination of nanotechnology and conventional tumor therapy can not only enhance the properties of chemoradiotherapy drugs but also reduce the incidence of poisoning and other side effects. These NPs can rapidly cross the human biological barriers, even in a targeted manner and continuously release the content to maintain the appropriate blood concentration of the drug.

Potential subtopics related to recurrent miscarriage include (but are not limited to):

• Bio/molecular nanosystems, nanoparticles including nanoscale bio/therapeutics and nano drug carriers, extracellular vesicles, smart and stimuli responsive nanobiosystems
• Nanotoxicity, nanotoxicology, biomedical sensors including sensor fusion
• Nanomedicine
• Gene therapy
• Biomimetic nanoengineering
• Single particle and single cell analysis, biomedical imaging, nanobiotechnology
• Photothermal therapy
• Nanomedicines in Skin cancer
• Nanomedicines in Lung cancer

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 December 2026.

Please submit your manuscript on our website, using the promo code E639F to indicate that your manuscript will be considered for this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisor

Prof. Veena Agrawal, University of Delhi

[email protected]

Professor Veena Agrawal, Senior Professor (R)of Botany (Level-15), University of Delhi, specializes in medicinal plant biotechnology, nanobiotechnology (green synthesis of nanoparticles and their efficacy against, different cancer cells, malaria vectors and diabetes), isolation and characterization of natural biomolecules, sex-linked molecular markers and genetic diversity analysis. She has published over 125 research articles in leading international journals with high impact factors, including Artificial Cells, Nanomedicines, Material Science and Engineering, Industrial Crops, Plant cell reports, Current Cancer Drug Target, Plant Science, Plant Physiology and Biochemistry, Process safety & Environmental Research, etc., Twenty five Ph. D and 21 M.phil. students obtained their degrees under her supervision in different disciplines. She is a Fellow of the Linnean Society of London (FLS) and a member of many international and national academic societies. She is on the editorial board of many journals including Arti. Cells Nanomedicines and Biotechnology. She is on the expert panels of international/national institutions for reviewing and evaluating research projects and Ph,D. theses. She has immensely contributed research to international and national platforms through presentations at conferences, seminars, and publications, as well as registering patents and receiving many awards and recognitions.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Nanotechnology, Science and Applications on "Uniting Natural Products and Biotechnology for the Next Generation of Nanomedicine", organized by Dr. Przemysław Sitarek (Medical University of Lodz, Poland) and Dr. Tomasz Kowalczyk (University of Lodz, Poland).

This Article Collection focuses on the convergence of nanotechnology, natural bioactive compounds, and biotechnology to develop advanced therapeutic approaches for a wide range of diseases. The integration of plant-derived phytochemicals, animal-based molecules, and recombinant proteins into nanoscale delivery systems opens new frontiers in precision medicine, offering improved biocompatibility, targeted delivery, and enhanced therapeutic efficacy. Recent advancements in biotechnology have enabled the design and production of engineered proteins and biomolecules with high specificity and functional versatility, further enriching the potential of nanomedical platforms. When combined with the diverse pharmacological properties of naturally sourced compounds, these hybrid nanosystems present promising strategies for treating cancer, infectious diseases, inflammatory conditions, metabolic disorders, and neurodegenerative diseases. This Collection invites original research, reviews, and perspectives that explore the design, synthesis, characterization, and biomedical application of nature-inspired and bioengineered nanostructures. The aim is to provide a multidisciplinary outlook on how the fusion of nanotechnology with natural and recombinant therapeutic agents can drive innovation in diagnosis, treatment, and regenerative medicine.

This Article Collection title encapsulates a timely and significant convergence of nanotechnology, biotechnology, and nature-derived bioactive compounds originating from plant and animal sources. In the context of escalating global health challenges—such as cancer, antimicrobial resistance, chronic inflammation, and neurodegenerative disorders—there is a pressing demand for the development of therapeutic strategies that are not only safe and effective, but also precisely targeted.

Natural molecules exhibit potent biological activity and favorable biocompatibility; however, their clinical potential is often limited by low stability and bioavailability. Advances in biotechnology and nanocarrier systems offer powerful tools to overcome these limitations by enhancing molecular stability, enabling controlled delivery, and improving therapeutic precision. The incorporation of recombinant proteins further broadens the therapeutic arsenal, supporting the design of personalized and multifunctional treatment modalities.

This title reflects the essence of an interdisciplinary approach that synergistically integrates nature’s pharmacological potential with the precision and adaptability of modern scientific innovation. It signals the emergence of a new era in nanomedicine—one in which nanoscale and molecular-level technologies converge to yield next-generation solutions for complex and treatment-resistant diseases.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 December 2026.

Please submit your manuscript on our website, using the promo code F4163 to indicate that your manuscript will be considered for this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Dr. Przemysław Sitarek, Medical University of Lodz

[email protected]

Przemysław Sitarek is an Associate Professor at the Medical University of Łódź (Poland), where he heads the Department of Medical Biology at the Faculty of Pharmacy. His interdisciplinary research spans biotechnology and nanotechnology, with a strong focus on biologically active compounds, recombinant proteins, and metabolic engineering. He is particularly interested in investigating metabolic pathways and developing nature-inspired biomedical solutions to address contemporary therapeutic challenges. His work contributes to advancing the role of both natural and engineered molecules in next-generation nanomedicine.

 Dr. Tomasz Kowalczyk, University of Lodz

[email protected]

Tomasz Kowalczyk, PhD, is an assistant professor in the Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Łódź and Department of Medical Biology, Faculty of Pharmacy, Medical University of Lodz. Research interests: Biotechnological production of natural biologically active compounds from plant and other natural sources Development of plant-based and microbial expression systems for production of valuable secondary metabolites and recombinant proteins Application of nanotechnology in combination with biotechnology.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Addiction in the Digital Age: Emerging Challenges in Neuropsychiatry" in Neuropsychiatric Disease and Treatment.

Behavioral addictions encompass a range of compulsive behaviors that, similar to substance use disorders, are characterized by neurobiological and psychological mechanisms. Despite the many positive effects of the rise of digitalization, problematic internet use, smartphone, video game, and social media addictions have been observed to increase steadily. In addition, gambling, exercise, shopping, eating, pornography, and sexual behavior addictions represent other significant types of behavioral addictions. The World Health Organization has emphasized that such addictions may affect a substantial proportion of the global population. Although each type of behavioral addiction exhibits unique features, they share common core characteristics, including emotional dysregulation, impulsivity, compulsivity, and disruptions in biological, psychological, social, and spiritual functioning. Addictions emerge from individuals’ pathological pursuit of reward and/or relief. Rewarding stimuli exert their effects through positive reinforcement mechanisms, while genetic variations related to the dopaminergic system, GABA, and other neurotransmitters shape behavioral outcomes. Understanding this multifaceted phenomenon requires an interdisciplinary approach encompassing neuroscience, psychology, and social sciences. Examining the prevalence of behavioral addictions, their associated components, and the underlying neuropsychiatric mechanisms through international research is expected to contribute significantly to a better understanding and prevention of addictions.

Global research reveals a significant increase in the prevalence of behavioral addictions. Technological advancements in the digital age put young people, the future of our world, at risk for various behavioral addictions, particularly technology addictions. These addictions, due to their increasing prevalence and their negative impact on individuals and society, are becoming a serious public health problem. In addition to exhibiting similar mechanisms of action to substance use disorders, such as dysregulated reward processing and impulsivity, they also increase mental health problems and lead to significant reductions in overall well-being and quality of life. The fact that they particularly affect younger generations and the ever-increasing rate of addiction highlights the urgent need for clinicians to address this issue. Therefore, addressing the prevalence of behavioral addictions, their associated factors, the neuropsychiatric mechanisms that contribute to them, and effective prevention and intervention are crucial to reducing their individual and societal burden and promoting healthier behavioral patterns.

With the rapid rise of digitalization, problematic internet use, smartphone, and social media addictions have steadily increased. Additionally, gambling, excessive exercise, shopping, eating, sexual behavior addictions represent other significant forms of behavioral addiction that may affect a substantial proportion of the global population, as highlighted by the World Health Organization. Despite their diversity, these conditions share core features such as emotional dysregulation, impulsivity, compulsivity, and impairments in biological, psychological, social, and spiritual functioning. Behavioral addictions stem from the pathological pursuit of reward and/or relief, often linked to dopaminergic pathways, GABAergic activity, and genetic variations influencing neurotransmission. Understanding this multifaceted phenomenon requires an interdisciplinary approach involving neuroscience, psychiatry, psychology, and social sciences. This Article Collection welcomes original research, systematic reviews, expert opinions, and extended reports that investigate the prevalence, underlying mechanisms, and related components of behavioral addictions through an international lens.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 980B8 to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 August 2026.

Please contact Sam Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Zeynep Öztürk, Erzurum Technical University

[email protected]

Dr. Zeynep Öztürk is an Assistant Professor of Psychiatric Nursing at Erzurum Technical University's Faculty of Health Sciences. She focuses on psychiatric nursing, mental health, addictions, resilience, spirituality in health, and elder care. She has published extensively in leading international journals in her field. She has authored over 20 publications indexed in Scopus and Web of Science. Dr. Öztürk also serves as a reviewer for several international journals and has led multiple clinical research projects.

Abdelaziz Hendy, Ain Shams University

[email protected]

Dr. Abdelaziz Said Hendy is an Assistant Professor of Pediatric Nursing at Ain Shams University, Egypt, and Assistant Professor at the College of Nursing, Qassim University, Saudi Arabia. He specializes in neonatal and pediatric nursing, nursing education, and public health. He serves as Academic Editor at PLOS ONE, Associate Editor at SAGE Open Nursing, and Editorial Board Member at BMC Nursing. With more than 50 publications indexed in Scopus and Web of Science, including contributions to The Lancet, his research focuses on advancing evidence-based neonatal and pediatric care. He is also an active reviewer for leading international journals and a member of the Scientific Council for the Neonatal Nursing Fellowship.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Cognitive Enhancement in Psychiatric Disorders" in Neuropsychiatric Disease and Treatment.

Cognitive impairment (CI) is prevalent in patients with various psychiatric conditions, e.g., schizophrenia, mood disorders, developmental disorders, and substance abuse. As CI is a major determinant of functional outcome, many years have been devoted to identifying treatment methods, including pharmacotherapy, rehabilitation and neuromodulation, that would effectively alleviate CI. While the evidence for the benefits of cognitive rehabilitation (remediation) therapy is relatively abundant, limited information has been available on cognition enhancing drugs (i.e., cognitive enhancers) that produce substantial effects on CI in psychiatric disorders.

Further efforts are needed to increase the chance of success of clinical trials evaluating cognitive enhancers, non-invasive brain stimulation methods, psycho-social intervention (cognitive rehabilitation/remediation). Importantly, such efforts should include the development of novel compounds or neuromodulation methods that show a greater ability to enhance cognitive function. Considerations should also be directed to the refinement of the study design, e.g., rational patient stratification and optimization of outcome measures. To effectively attain these goals, cutting-edge knowledge of the neurobiology of CI associated with psychiatric illnesses is required.

Prospective papers will deal with genetic, molecular, imaging, physiological, psychological, and/or behavioral issues regarding the mechanisms, assessment, and treatment of CI in psychiatric illnesses. Types of articles include Original Research, Reviews, Study Protocols, and Letter to the Editor. Also, Expert Opinion and Perspectives may be requested by Guest Advisor with an invitation basis. Overall, this Topic will provide the up-to-date knowledge on the mechanisms of CI associated with psychiatric illnesses and its treatment strategies, which will help facilitate social inclusion of patients and caregivers.

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 3A5AF to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 August 2026.

Please contact Sam Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Radiation Therapies for Cancer" in OncoTargets and Therapy.

Radiation therapy remains a cornerstone in the treatment of various cancers. With continuous advancements in technology and a deeper understanding of cancer biology, radiation therapies are becoming more precise and effective. This Article Collection seeks to explore these advancements, including novel radiation techniques, toxicity management, and integration of radiation therapies with other treatment modalities.

We invite papers on topics including but not limited to:

• Innovative radiation techniques, including proton therapy, carbon ion therapy, and stereotactic body radiotherapy (SBRT).
• Technological innovations in radiation oncology, including the development and implementation of technologies such as artificial intelligence, machine learning, and image-guided radiation therapy (IGRT) in clinical practice.
• Radiation therapy and immunotherapy combinations.
• Personalized radiation therapy
• Radiation-induced toxicity management

The deadline for submissions is 1 December 2025. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code MMCTR for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection entitled “Breaking Down the Intricacies of Catabolic Enzymes”, organized by Editor-in-Chief Dr. Martin Bluth in Pharmacogenomics and Personalized Medicine.

Genetic polymorphisms are one way in which people vary from one another. While initial thoughts of "variance" might include a person’s physical features, it is well established that the body’s internal processes are also subject to differ dependent on a multitude of factors. This could include traits that follow them from birth, but also polypharmacy, or even diet.

In line with the advances in modern medicine and genetic testing, research has started to explore the plethora of information linked to catabolic enzyme polymorphisms. This can involve specifying polymorphisms of interest, such as the Cytochrome P450 (CYP) family such as those including the location on the chromosome, possible allelic variations and the impact of these polymorphisms on their parent compound, metabolites or other molecules.

Genetic polymorphisms affect many parts of human function, irrespective of specific health status. This stresses the importance of such polymorphisms further, for both promoting wellbeing in times of health, but to also understand how to approach certain illnesses given the variance in each individual case. This Collection aims to explore the role of catabolic enzyme polymorphisms for a wide variety of disease areas, such as oncology, pulmonology, immunology, psychology, cardiology and more.

The advances in medicine can also leave researchers asking more questions. As more drug compounds reach regulators and medicine agencies, should we be considering how enzyme polymorphisms influence the efficacy and reaction of new medicines? What dangers exist when you inhibit or enhance an enzyme reaction? When considering these possibilities for new medicines, it is also imperative to acknowledge the range of possible reactions and their severity, given that polymorphisms highlight how differences between people should not be underestimated. In turn it is hoped that this Article Collection can promote best practices when prescribing treatments, by placing leading research in this collection.

It is also hoped that research can investigate catabolic enzyme polymorphisms with a wider lens, to understand global trends in such polymorphisms and our understanding of variance on a larger scale. Thus, exploring upcoming topics of interest in this field, such as genomic testing and the use of bioinformatics in predictive technologies, elucidating the intricacies of such interaction are now within reach. These possibilities may provide more control to the individual, their medical practitioners, drug manufacturers by acknowledging human variance stretches beyond what meets the eye. These investigations, questions and early research outcomes highlight the importance of this topic for sustaining our health as a population.

The journal is seeking original submissions and review articles from all disease areas on the following topics related to catabolic enzyme polymorphisms:

• Identifying and understanding polymorphisms (e.g., single-nucleotide polymorphisms)
o All aspects of enzyme metabolism (e.g., catabolism, anabolism)
o Associated mutations, location and allelic compositions
o Functions of interest (e.g., CYPs, steroidogenic enzymes)
• Incidence and variance of poor metabolizers
• Biochemical impact of polymorphisms (e.g., on parent compound, metabolites)
• Impact of polymorphisms on drug reaction symptoms, severity and consequences
o Variance in pro-drug and active drug reactions
• Non-drug consumables (i.e. diet, infectious diseases) and polymorphisms
• How epigenetic and infectious processes affect polymorphism function
• Treatment efficacy and polymorphisms
o Role of polypharmacy on reactions
o Personalized dosages, drug classes and emergency medical care
• Global trends and variation in polymorphisms
• Progress in polymorphism genomic testing and associated benefits and costs
• Use of bioinformatics and modelling systems for predictive testing

All manuscripts submitted to this Article Collection are subject to desk assessment and peer review processes as part of our standard editorial process. We kindly ask all submitting authors to review the Aims and Scope of the journal, alongside the Author Information prior to completing your submission.

The deadline for submissions is 31 May 2024.

Please submit your manuscript on our website, quoting the promo code XSMPT for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Navigating Complexity: Real-World Evidence of Biologics in Elderly and Multimorbid Psoriasis Patients" in Psoriasis: Targets and Therapy.

The therapeutic landscape of psoriasis has been revolutionized by the advent of biological agents, offering unprecedented levels of skin clearance and quality of life improvement. However, randomized controlled trials (RCTs) often employ strict inclusion criteria, leading to the underrepresentation of specific patient subgroups commonly encountered in daily practice, such as the elderly (including the "oldest old") and patients with significant multiple comorbidities. As the global population ages and the systemic nature of psoriasis becomes increasingly evident, bridging the gap between controlled trial environments and clinical reality is imperative. This Article Collection focuses on Real-World Evidence (RWE) regarding the use of biologics in these complex scenarios. We aim to gather data that elucidates how biological therapies perform outside the rigid constraints of RCTs, specifically targeting vulnerable populations where evidence-based guidance is often limited or extrapolated.

This Collection is crucial because clinicians frequently face the challenge of treating psoriatic patients who do not fit the "standard" profile of RCT participants. The management of psoriasis in the elderly is complicated by immunosenescence, polypharmacy, and frailty, while the presence of comorbidities—ranging from cardiovascular and metabolic diseases to malignancies—poses significant safety concerns and therapeutic dilemmas. Understanding the bidirectional relationship between psoriasis treatment and comorbidities is vital: not only how comorbidities influence effectiveness, safety and drug survival, but also how biologics might modify the natural history of associated conditions (e.g., potential cardio-protective effects or cancer risks). Collecting high-quality real-world data is essential to validate the long-term safety profile of these drugs, tailor treatments to individual phenotypic profiles, and ultimately optimize the risk-benefit ratio for the most fragile patients.

This Article Collection welcomes submissions that investigate the practical application of biological therapies in psoriasis, with a specific lens on complex patient profiles. We encourage the submission of Original Research, Reviews, and Real-World Case Series. Key subtopics of interest include, but are not limited to:
• Effectiveness and Safety in the Elderly: Impact of immunosenescence on biologic response and infection risk in geriatric populations;
• Comorbidities and Treatment Response: How metabolic syndrome, diabetes, chronic kidney disease (CKD) or cardiovascular disease influence effectiveness, safety and drug survival;
• Impact of Biologics on Comorbidities: Research into the potential protective effects of systemic inflammation reduction on organs and systems affected by chronic diseases, as well as the risk of disease progression;
• Malignancy: Real-world data on the safety of biologics in patients with a history of cancer or concurrent malignancies;
• Polypharmacy: Drug-drug interactions and management strategies in multimorbid patients.

Keywords

1. Real-world evidence
2. Biologics
3. Psoriasis comorbidities
4. Geriatric dermatology
5. Drug survival

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 5 November 2026.

Please submit your manuscript on our website, quoting the promo code 5E799 to indicate that your submission is for consideration in this Article Collection.

Guest Advisors

Dr Zeno Fratton, University of Udine

[email protected]

Dr. Zeno Fratton is a physician based at the Institute of Dermatology, University of Udine (Italy). His research focuses on chronic inflammatory skin diseases, particularly plaque psoriasis and biological therapies in the elderly and other special populations. He has authored numerous papers in high-impact journals and serves as a reviewer for top-tier publications. He graduated with honors from the University of Verona under the guidance of Prof. Paolo Gisondi and is an active member of the Italian Society of Pediatric Dermatology (SIDerP).

Dr. Stefano Bighetti, University of Brescia

[email protected]

Dr. Stefano Bighetti is a dermatologist at the Dermatology Department, University of Brescia (Italy), with a clinical and academic focus on chronic inflammatory skin diseases, particularly atopic dermatitis and psoriasis, and on non-invasive therapeutic strategies including phototherapy and laser-based therapies. He has authored and co-authored several peer-reviewed publications in the international dermatology literature, with contributions spanning clinical research and real-world evidence. He serves on the Editorial Board of the Italian Journal of Dermatology and Venereology and acts as a peer reviewer for multiple dermatology journals. He is engaged in academic and educational activities within national scientific societies, supporting initiatives in continuing medical education and evidence-based dermatology.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “Problematic Use of Smartphones and Social Media: Psychological, Behavioral, and Societal Perspectives” in Psychology Research and Behavior Management.

Smartphone and social media use have become deeply embedded in contemporary daily life, fundamentally reshaping how individuals communicate, learn, and socially interact. While these technologies offer remarkable opportunities for connection and information access, their excessive and unregulated use has raised growing concerns about problematic and disordered usage patterns, well-being, and mental health outcomes. Rather than framing these concerns solely through the lens of problematic use of smartphones and social media, this Article Collection adopts a broader and more nuanced perspective, recognizing that problematic smartphone and social media use exists on a continuum, from habitual overuse to clinically significant disordered engagement. With individuals across diverse age groups and cultural contexts reporting increasing difficulties in regulating their digital behaviors, this Collection seeks to examine the psychological, behavioral, and social dimensions of problematic technology use. Particular attention will be given to novel pathways of digital self‑regulation, measurable behavioral indicators such as usage patterns and executive functioning, and adaptive strategies grounded in prior evidence yet tailored to emerging challenges.

Understanding problematic use of smartphones and social media is critical for addressing its impact on mental health, interpersonal relationships, and societal structures. Excessive use has been associated with anxiety, depression, social isolation, and other well-being and mental health outcomes. At the same time, digital platforms shape identity, influence decision-making, and redefine cultural norms. By examining these dynamics, researchers can identify novel pathways through which technology use influences psychological well‑being and social development. This Collection will deliver focused, evidence‑based insights into issues such as self‑regulation, executive functioning, and social‑emotional isolation, highlighting how these factors uniquely affect outcomes in diverse populations. In doing so, it moves beyond general discussions of technology use and offers practical implications for clinicians, educators, and policymakers.

This Article Collection welcomes empirical studies, theoretical papers, systematic reviews, and intervention-based research that address problematic and disordered smartphone and social media use within the scope of psychology and behavior management. Subtopics of particular interest include: measurable behavioral mechanisms such as self-control failures, habit formation, urge regulation, and tolerance or withdrawal-like phenomena; psychosocial and cognitive correlates of disordered digital use; the role of executive functioning and self-regulation in technology-related behaviors; well-defined mental health and behavioral outcomes examined through longitudinal and interventional research designs; cross-cultural validation of measurement tools and theoretical frameworks; and the impact of digital platforms on youth, families, and communities. Interdisciplinary contributions integrating perspectives from psychology, public health, education, and behavioral science are strongly encouraged. Preferred article types include original research articles, pre-registered studies, systematic reviews, and conceptual analyses that advance both theoretical understanding and practical application.

Keywords

• Problematic smartphone use
• Disordered social media use
• Self-regulation and habit formation
• Mental health and well-being
• Cross-cultural validation

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 11 February 2027.

Guest Advisor

Professor Murat Yıldırım, Agri Ibrahim Cecen University

[email protected]

Murat Yildirim, PhD, is an Associate Professor of Psychology, working at Agri Ibrahim Cecen University, Türkiye. His research focuses on psychosocial factors influencing well-being, mental health outcomes, and individuals differences. He has published extensively in peer-reviewed journals and collaborates internationally on projects related to digital addiction and psychosocial factors affecting well-being and mental health outcomes.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection "Healthcare for Cardiorenal Chronic Patients: A Challenge for Social Expenditure", organized by Prof. Caterina Carollo and Prof. Siddiq Anwar in Risk Management and Healthcare Policy.

Cardiorenal syndromes represent a growing global health challenge, characterized by the complex interplay between heart and kidney dysfunction. These conditions are becoming increasingly prevalent, requiring long-term management and multidisciplinary care. The treatment of cardiorenal patients often involves collaboration among various healthcare professionals, which contributes to rising healthcare costs and places significant strain on social expenditure. This Article Collection aims to explore innovative solutions that balance optimal treatment outcomes with sustainable healthcare costs, addressing a pressing issue that affects healthcare systems worldwide, regardless of whether they are public or private.

The rising prevalence of cardiorenal syndromes poses significant challenges to healthcare systems worldwide. These conditions require long-term management and multidisciplinary care, which can strain healthcare resources and increase social expenditure. This Article Collection seeks to address these challenges by fostering research that identifies cost-effective strategies for managing cardiorenal patients. By advancing our understanding of integrated care models and innovative healthcare policies, this Collection aims to provide a foundation for improving patient outcomes while ensuring the sustainability of healthcare systems. The insights gained will be invaluable for policymakers, healthcare providers, and researchers working to mitigate the global impact of these chronic conditions.

We invite submissions that explore integrated and transitional care approaches for cardiorenal patients, including strategies to reduce hospital stays and enhance the quality of life for individuals with chronic heart and kidney failure. Topics of interest include home healthcare models, the role of nursing and healthcare professionals, and innovative interventions to optimize patient outcomes. Additionally, we welcome research articles, reviews, and perspectives that examine the challenges of managing cardiorenal syndromes and propose solutions for sustainable healthcare management. By addressing these diverse aspects, this Collection aims to foster a multidisciplinary dialogue that advances both clinical practice and healthcare policy.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 October 2026.

Please submit your manuscript on our website, quoting the promo code 6F64B to indicate that your submission is for consideration in this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Dr. Caterina Carollo, University of Palermo, Italy

[email protected]

Dr Prof. Caterina Carollo is a nephrologist and researcher with extensive expertise in cardiorenal physiology, hypertension, and microcirculation. She holds a PhD in Cardiovascular and Renal Clinical Pathophysiology and has authored numerous publications in high-impact journals, focusing on innovative approaches to nephrocardiology and oxidative stress. Dr. Carollo is also an experienced educator, currently teaching Nephrology at the University of Palermo, and has played a pivotal role in organizing and leading prominent scientific conferences in her field.

Dr. Siddiq Anwar, Khalifa University, United Arab Emirates

[email protected]

Dr. Siddiq Anwar is a Consultant Nephrologist and Clinical Professor at Sheikh Shakhbout Medical City, with academic appointments at Khalifa University, UAE University, and Gulf Medical University, and a Visiting Fellowship at the ADIA Lab focusing on AI-driven cardiorenal care optimization. He has led transformative digital health programs across GCC healthcare systems, specializing in integrated chronic disease management, population health outcomes, and sustainable care delivery models. Dr. Anwar co-founded RenAIssance AI research laboratory and has extensive experience developing cost-effective healthcare solutions across the Middle East, Africa, and South Asia.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Risk Management and Healthcare Policy on "Resilient Health Systems and Policy Responses in Public Health Crises", organized by Prof. Munjae Lee (Yonsei University, South Korea).

Public health crises place significant pressure on healthcare systems, disrupting the continuity of essential services and exposing structural vulnerabilities across care delivery. Events such as pandemics amplify existing inequalities in access to care, inefficiencies in resource allocation, and limitations in infrastructure readiness. These disruptions are further compounded by uncertainty and systemic risks that challenge traditional models of healthcare delivery. Addressing these challenges requires integrated strategies that strengthen health system resilience, enhance risk management capacity, and enable adaptive and data-informed responses to rapidly evolving health needs. This Article Collection aims to explore evidence-based approaches to improving health system resilience while ensuring continuity of essential services during public health crises.

The importance of resilient and risk-responsive healthcare systems has become increasingly evident as large-scale crises generate widespread social and economic disruption. These conditions place pressure on healthcare delivery systems, strain workforce capacity, and exacerbate inequities in access to care. Such challenges reveal critical gaps in risk governance, policy coordination, and system-level decision-making under uncertainty. Without adaptive and data-informed policy frameworks, these disruptions may lead to long-term consequences, including rising healthcare costs, reduced system efficiency, and widening health inequalities. Strengthening healthcare systems therefore requires coordinated policy responses, effective governance mechanisms, and strategic resource allocation to ensure system resilience and sustainable recovery.

This Article Collection invites original research, policy analyses, short reports, case studies, and perspectives that examine health system resilience, risk governance, and policy responses during public health crises.

Topics of interest include, but are not limited to:

• Health system preparedness, resilience, and continuity of essential services during public health crises
• Risk governance, emergency policy coordination, and decision-making under uncertainty
• Healthcare utilisation, access inequities, and service disruption in crisis settings
• Community-based care models and service continuity, including mental health as one component
• Workforce resilience, patient safety, and adaptive healthcare delivery
• Risk-informed resource allocation, triage policy, and health economic evaluation during emergencies
• Data-informed surveillance, forecasting, and decision support with clear policy relevance
• Comparative evaluations of crisis response policies across healthcare systems

By integrating multidisciplinary perspectives, this Collection aims to generate actionable insights that support policy-relevant, data-informed decision-making and strengthen resilient healthcare systems in the face of future public health crises.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 January 2027.

Please submit your manuscript on our website, quoting the promo code 75080 to indicate that your submission is for consideration in this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisor

Prof. Munjae Lee, Yonsei University

[email protected]

Dr. Munjae Lee is an Associate Professor in the Department of Biohealth Industry at Yonsei University. His research focuses on healthcare system resilience, risk management, and digital health innovation in the biohealth sector. He has led multiple national and international research projects on healthcare policy, medical device ecosystems, and AI-enabled healthcare innovation, with a particular emphasis on system-level decision-making under uncertainty. Dr. Lee serves as an Associate Editor and Editorial Board Member for several international journals, contributing to advancing research in health systems, policy, and innovation.

View all papers in this article collection

We are pleased to announce a new Article Collection in Therapeutics and Clinical Risk Management, titled: Circulating Biomarkers and AI in Therapeutics and Clinical Risk Management: From Molecular Signals to Precision Medicine.

Circulating biomarkers are increasingly reshaping the landscape of modern medicine by enabling minimally invasive, dynamic assessment of disease processes across diverse clinical settings. Among these, cell-free DNA (cfDNA) has emerged as a particularly versatile analyte, offering insights into tissue damage, clonal evolution, and therapeutic response in real time. Beyond its established role in oncology, cfDNA and related circulating markers are gaining traction in cardiovascular disease, transplantation monitoring, infectious diseases, and chronic inflammatory conditions, where early detection and longitudinal surveillance remain critical challenges. At the same time, the growing complexity and volume of biomarker-derived data have accelerated the integration of artificial intelligence (AI) and machine learning approaches, which enable more robust interpretation, risk prediction, and clinical decision support. Together, these advances are driving a shift toward data-informed, precision-based therapeutics and more proactive clinical risk management strategies.

This topic is particularly important because many current clinical paradigms still rely on static, late-stage indicators that fail to capture the dynamic and heterogeneous nature of disease progression. As a result, opportunities for early intervention, timely treatment adjustment, and precise risk stratification are often missed. Circulating biomarkers, especially when assessed longitudinally, offer a unique window into ongoing biological processes, enabling earlier detection of relapse, identification of therapeutic resistance, and more accurate monitoring of treatment efficacy. However, the clinical utility of these signals is frequently limited by their complexity and context dependency, which cannot be fully resolved through conventional analytical approaches alone. The integration of AI provides a critical solution by uncovering hidden patterns, modeling temporal changes, and combining multi-dimensional data into clinically actionable insights. Together, these advances have the potential to transform reactive healthcare models into proactive, predictive, and personalized systems.

This Collection will focus on the clinical application and translational potential of circulating biomarkers and AI in therapeutic decision-making and risk management across a range of disease settings. Particular emphasis will be placed on studies evaluating cfDNA and other liquid biopsy approaches for treatment monitoring, minimal residual disease detection, and early identification of therapeutic resistance, as well as biomarker-driven patient stratification and prognosis. Contributions exploring the integration of multi-omics data with clinical variables, imaging, and real-world datasets using AI-based models are especially encouraged, provided they demonstrate clear relevance to clinical practice. In line with the journal’s scope, submissions should prioritize clinical utility, validation, and implementation rather than purely exploratory analyses. We welcome original research articles, systematic reviews, and clinically oriented narrative reviews, as well as studies leveraging real-world evidence to inform therapeutic strategies and risk prediction in routine care settings.

Keywords

• Circulating Biomarkers
• Cell-free DNA (cfDNA)
• Artificial Intelligence in Healthcare
• Precision Medicine
• Clinical Risk Stratification

All manuscripts submitted to this Article Collection will undergo desk assessment and peer review if they can pass the desk assessments as part of our standard editorial process; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please submit your manuscript on our website. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 December 2026.

Please contact Catherine Teng at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisor

Dr Hengrui Liu, University of Cambridge

[email protected]

Hengrui Liu holds a PhD in Biochemistry from the University of Cambridge and is currently a Research Associate at the Early Cancer Institute, University of Cambridge, as well as a Visiting Scientist at the CRUK Cambridge Institute. His research focuses on cancer biology, liquid biopsy, and biomarker development, with a strong interest in translational and multi-omics approaches. He has been recognized among the Stanford-Elsevier World’s Top 2% Scientists and has received multiple international awards for his academic contributions.

View all papers in this article collection

We are pleased to announce a new Article Collection in Therapeutics and Clinical Risk Management, titled: Current and Emerging Strategies in the Management of Cardiac Arrhythmias.

Cardiac arrhythmias remain a major cause of morbidity, mortality, hospitalization, and impaired quality of life worldwide. They encompass a broad and increasingly complex spectrum of disorders, ranging from atrial fibrillation and supraventricular tachycardias to ventricular arrhythmias, conduction disease, and inherited arrhythmic syndromes. Over the past few years, the field has evolved rapidly, driven by major advances in catheter ablation technologies, physiological pacing, multimodality imaging, digital diagnostics, and data-enabled clinical decision-making. In particular, pulse field ablation has reshaped the contemporary atrial fibrillation ablation landscape, while conduction system pacing has emerged as a major development in device therapy. At the same time, artificial intelligence, wearable devices, and remote monitoring are redefining how arrhythmias are detected, risk-stratified, and followed longitudinally. This Article Collection will provide a contemporary forum for high-quality work addressing both established and emerging strategies in arrhythmia management across a wide range of clinical settings.

This topic is particularly timely because arrhythmia care is entering a phase of substantial therapeutic and technological transition. Traditional management models based largely on symptom status and broad rhythm categories are increasingly being replaced by more individualized approaches that integrate substrate characterization, disease stage, comorbidity burden, procedural strategy, and continuous rhythm surveillance. New ablation platforms, especially pulse field ablation, have raised important questions regarding comparative efficacy, safety, lesion durability, procedural efficiency, and patient selection. Similarly, the expansion of conduction system pacing is reshaping practice in bradyarrhythmia management and cardiac resynchronization. Meanwhile, digital health tools and AI-enabled analytics are creating new opportunities for earlier diagnosis, outcome prediction, and more precise follow-up, but they also introduce challenges related to validation, implementation, workflow integration, and clinical interpretability. Bringing these developments together in one Collection is important not only for summarizing current evidence but also for identifying where genuine innovation is improving patient care and where critical knowledge gaps remain.

This Article Collection welcomes submissions spanning the full spectrum of contemporary arrhythmia management. Topics of particular interest include atrial fibrillation screening and prevention; catheter ablation strategies for atrial and ventricular arrhythmias; pulse field ablation and other evolving energy sources; substrate-based ablation and adjunctive lesion-set strategies; conduction system pacing and advances in cardiac implantable electronic devices; sudden cardiac death prevention; management of electrical storm and complex ventricular arrhythmias; inherited arrhythmia syndromes and cardiogenetics; imaging-guided electrophysiology; wearable technologies and remote rhythm monitoring; artificial intelligence and predictive analytics in arrhythmia care; and arrhythmia management in patients with heart failure, diabetes, obesity, chronic kidney disease, and other high-risk comorbid conditions. The Collection would particularly benefit from original clinical studies, translational investigations, state-of-the-art reviews, systematic reviews and meta-analyses, expert perspectives, and clinically focused narrative reviews that bridge mechanistic insight with therapeutic relevance and risk management.

Keywords

• Cardiac arrhythmias
• Atrial fibrillation
• Catheter ablation
• Conduction system pacing
• Digital health and artificial intelligence

All manuscripts submitted to this Article Collection will undergo desk assessment and peer review if they can pass the desk assessments as part of our standard editorial process; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please submit your manuscript on our website. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 December 2026.

Please contact Catherine Teng at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisor

Dr Paschalis Karakasis, Aristotle University of Thessaloniki (AUTH)

[email protected]

Paschalis Karakasis is a cardiologist and research fellow at the Second Department of Cardiology, Aristotle University of Thessaloniki, Hippokration General Hospital, Greece. His academic and clinical work is focused on cardiac electrophysiology, particularly atrial fibrillation, catheter ablation, and next-generation strategies in arrhythmia management. He has built a growing body of work in cardiovascular research through high-level reviews, meta-analyses, and clinically oriented publications spanning electrophysiology and cardiometabolic disease. His broader interest is to help shape a more precise, evidence-driven, and technologically integrated future for cardiovascular medicine.

View all papers in this article collection

We are pleased to announce a new Article Collection in Therapeutics and Clinical Risk Management, titled: Novel Biomarkers and Molecular Biology of Solid Tumors.

Solid tumors are biologically heterogeneous diseases shaped by dynamic interactions among genomic alterations, epigenetic states, transcriptional programs, the tumor microenvironment, and host factors. As a result, there is growing interest in biomarkers that can capture tumor behavior more accurately than conventional clinicopathologic variables alone. This Article Collection will focus on emerging biomarkers and molecular mechanisms relevant to solid tumors, spanning tissue-based and liquid-biopsy approaches, multi-omic profiling, and mechanistic studies that clarify how molecular alterations drive tumor initiation, progression, metastatic spread, and therapeutic response. The Collection aims to bring together contributions that bridge discovery science and translational oncology, with particular attention to robust biomarker development, biological interpretation, and clinically meaningful applications across common and rare solid malignancies.

This topic is important because the clinical management of solid tumors increasingly depends on precise molecular stratification. Reliable biomarkers can improve early detection, refine diagnosis, support prognosis, identify patients most likely to benefit from targeted or immune-based therapies, and enable longitudinal monitoring of response, minimal residual disease, and resistance. At the same time, many promising markers remain insufficiently validated, biologically underexplained, or difficult to translate across platforms and clinical settings. A focused collection on this subject can help connect mechanistic tumor biology with practical biomarker implementation, highlighting not only novel discoveries but also the methodological and interpretative challenges that determine whether a biomarker becomes clinically useful. This is especially timely as integrated molecular diagnostics, digital pathology, and longitudinal sampling are reshaping precision oncology.

We welcome original research articles, reviews, and other article types supported by the journal that address molecular and biomarker-driven research in solid tumors. Relevant subtopics include discovery and validation of diagnostic, prognostic, and predictive biomarkers; tumor genomics, epigenomics, transcriptomics, proteomics, metabolomics, and spatial profiling; biomarkers derived from circulating tumor DNA, circulating tumor cells, exosomes, and other liquid-biopsy analytes; tumor microenvironment and immune-related markers; mechanisms of treatment sensitivity and resistance; biomarker-guided therapeutic strategies; digital pathology and computational or AI-assisted biomarker analysis; assay development, standardization, and translational studies that link molecular findings to patient stratification and clinical decision-making across solid tumor types.

Keywords

• Solid tumors
• Biomarkers
• Molecular oncology
• Liquid biopsy
• Precision medicine

All manuscripts submitted to this Article Collection will undergo desk assessment and peer review if they can pass the desk assessments as part of our standard editorial process; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please submit your manuscript on our website. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 January 2027.

Please contact Catherine Teng at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisor

Dr. Vincenzo Fiorentino, University of Messina

[email protected]

Vincenzo Fiorentino, MD, is an anatomic pathologist and academic researcher at the University of Messina. His main areas of expertise include hematopathology, gastrointestinal pathology, thyroid pathology, uropathology, and cytopathology. His academic and scientific work has been devoted to the investigation of pathological mechanisms and diagnostic challenges in these fields, with a focus on the integration of histopathology, cytopathology, and ancillary diagnostic methods.

View all papers in this article collection